

Approved



**Malawi**

**Country Operational Plan**

**FY 2014**

Note: Italicized sections of narrative text indicate that the content was not submitted in the Lite COP year, but was derived from the previous Full COP year. This includes data in Technical Area Narratives, and Mechanism Overview and Budget Code narratives from continued mechanisms.



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Total
	GAP	GHP-State	GHP-USAID	
DOD		2,300,000		2,300,000
HHS/CDC	1,512,500	27,332,447		28,844,947
HHS/HRSA		5,198,799		5,198,799
PC		1,293,564		1,293,564
State		194,522		194,522
State/AF		1,880,000		1,880,000
USAID		25,980,494	15,500,000	41,480,494
<b>Total</b>	<b>1,512,500</b>	<b>64,179,826</b>	<b>15,500,000</b>	<b>81,192,326</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency								On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID	AllOther		
CIRC	0	566,667	765,379	1,500,000			2,974,632		0	5,806,678
HBHC	10,300	93,333	2,316,197		79,735	45,000	5,485,343		0	8,029,908
HKID	10,300				34,769	30,000	4,915,135		0	4,990,204
HLAB			1,304,079				176,563		0	1,480,642
HMBL			1,764,659						0	1,764,659
HMIN	0									0
HTXS		310,000	11,297,613	2,055,000			7,227,180		0	20,889,793
HVAB	0				15,202		261,340		0	276,542
HVCT	0	256,667	686,274		0		1,503,546		0	2,446,487
HVMS	134,192	56,667	2,343,334		1,063,567		37,762		0	3,635,522
HVOP	0	156,667			43,555		3,082,022		0	3,282,244
HVSI	4,414	243,333	647,826	503,458			324,168		0	1,723,199

Approved



HVTB	8,829	103,333	1,002,373	140,000			2,587,491		0	<b>3,842,026</b>
MTCT	5,886	306,667	974,656	250,341			2,914,429		0	<b>4,451,979</b>
OHSS	2,943	103,333	2,220,656	700,000	56,736	1,805,000	3,930,452		0	<b>8,819,120</b>
PDCS	8,829		1,573,435				2,560,282		0	<b>4,142,546</b>
PDTX	8,829	103,333	1,948,466	50,000			3,500,149		0	<b>5,610,777</b>
	<b>194,522</b>	<b>2,300,000</b>	<b>28,844,947</b>	<b>5,198,799</b>	<b>1,293,564</b>	<b>1,880,000</b>	<b>41,480,494</b>	<b>0</b>	<b>0</b>	<b>81,192,326</b>



## Budgetary Requirements Worksheet

Redacted

### Technical Areas

#### Technical Area Summary

##### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	7,252,369	0
HKID	4,653,677	0
HVTB	3,235,388	0
PDCS	3,512,689	0
<b>Total Technical Area Planned Funding:</b>	<b>18,654,123</b>	<b>0</b>

##### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	1,448,418	0
HVSI	1,615,418	0
OHSS	8,563,426	0
<b>Total Technical Area Planned Funding:</b>	<b>11,627,262</b>	<b>0</b>

##### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	5,545,250	0
HMBL	1,760,868	0
HVAB	180,488	0
HVCT	2,327,604	0

Approved



HVOP	3,060,000	0
MTCT	4,245,588	0
<b>Total Technical Area Planned Funding:</b>	<b>17,119,798</b>	<b>0</b>

**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>	<b>On Hold Amount</b>
HTXS	19,527,010	0
PDTX	4,983,192	0
<b>Total Technical Area Planned Funding:</b>	<b>24,510,202</b>	<b>0</b>



### Technical Area Summary Indicators and Targets

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	1,123	389
	By program area/support type: HTC Direct Service Delivery (DSD)	147	386
	By program area/support type: HTC Technical Assistance-only (TA)	587	
	By program area/support type: Treatment Direct Service Delivery (DSD)	104	385
	By program area/support type: Treatment Technical Assistance-only (TA)	553	
	By program area/support type: Care and Support Direct Service Delivery (DSD)	181	389
	By program area/support type: Care and Support Technical Assistance-only (TA)	448	
	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	5	4
	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0



	By program area/support type: PMTCT Direct Service Delivery (DSD)	103	374
	By program area/support type: PMTCT Technical Assistance-only (TA)	517	
	By program area/support type: TB/HIV Direct Service Delivery (DSD)	158	
	By program area/support type: TB/HIV Technical Assistance-only (TA)	243	
	By program area/support type: VMMC Direct Service Delivery (DSD)	62	63
	By program area/support type: VMMC Technical Assistance-only (TA)	0	0
	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	105	30
	By program area/support type: General Population Prevention Technical Assistance-only (TA)	90	13
	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	12	8
	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0
	By program area/support	112	113



	type: OVC Direct Service Delivery (DSD)		
	By program area/support type: OVC Technical Assistance-only (TA)	5	0
	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	226	150
	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	57	205
	By program area/support type: Lab Direct Service Delivery (DSD)	60	8
	By program area/support type: Lab Technical Assistance-only (TA)	92	144
PMTCT_SITE	PMTCT_SITE Percentage of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	n/a	
	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women		374
	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)		374
	By site support type: Direct Service Delivery (DSD):		374



	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women		
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women		
	Sum of Numerator Support Type disaggregates		374
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)		374
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)		
	Sum of Denominator Support Type disaggregates		374
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	90 %	
	Number of pregnant women	113,718	476,599



	with known HIV status (includes women who were tested for HIV and received their results)		
	Number of new ANC and L&D clients	126,353	515,208
	By: Known positives at entry		21,415
	By: Number of new positives identified		24,149
	Sum of Positives Status disaggregates		45,564
	Required only for DREAMS Countries - By Number of new positives: <15		
	Required only for DREAMS Countries - By Number of new positives: 15-19		
	Required only for DREAMS Countries - By Number of new positives: 20-24		
	Required only for DREAMS Countries - By Number of new positives: 25+		
	Required only for DREAMS Countries - By Number of known positives: <15		
	Required only for DREAMS Countries - By Number of known positives: 15-19		
	Required only for DREAMS Countries - By Number of known positives: 20-24		
	Required only for DREAMS Countries - By Number of known positives: 25+		



	Required only for DREAMS Countries - Denominator: <15		
	Required only for DREAMS Countries - Denominator: <15-19		
	Required only for DREAMS Countries - Denominator: 20-24		
	Required only for DREAMS Countries - Denominator: 25+		
PMTCT_STAT_NGI	PMTCT_STAT_NGI Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (NGI)	90 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	581,046	
	Number of new ANC and L&D clients	645,606	
	By: Known positives at entry		
	By: Number of new positives identified		
	Sum of Positives Status disaggregates		
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received	90 %	



	their results) (TA)		
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	467,328	
	Number of new ANC and L&D clients	519,253	
	By: Known positives at entry		
	By: Number of new positives identified		
	Sum of Positives Status disaggregates		
	Required only for DREAMS countries - By known positives: <15		
	Required only for DREAMS countries - By known positives: 15-19		
	Required only for DREAMS countries - By known positives: 20-24		
	Required only for DREAMS countries - By known positives: 25+		
	Required only for DREAMS countries - By new positives: <15		
	Required only for DREAMS countries - By new positives: 15-19		
	Required only for DREAMS countries - By new positives: 20-24		
	Required only for DREAMS		



	countries - By new positives: 25+		
	Required only for DREAMS countries - Denominator: <15		
	Required only for DREAMS countries - Denominator: 15-19		
	Required only for DREAMS countries - Denominator: 20-24		
	Required only for DREAMS countries - Denominator: 25+		
PMTCT_ARV_DSD	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	93 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	7,328	41,101
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	7,880	45,564
	Life-long ART (including Option B+)	7,328	41,101
	Sub-Disag of Life-long ART:	4,617	20,551



	Newly initiated on treatment during the current pregnancy		
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,711	20,550
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
	Single-dose nevirapine (with or without tail)	0	0
	Sum of Regimen Type disaggregates	7,328	41,101
	Sum of New and Current disaggregates	7,328	41,101
PMTCT_ARV_NGI	PMTCT_ARV_NGI Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (NGI)	93 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	44,047	



	and delivery		
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	47,362	
	Life-long ART (including Option B+)	44,047	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	27,750	
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	16,297	
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
	Single-dose nevirapine (with or without tail)	0	
	Sum of Regimen disaggregates	44,047	
	Sum of New and Current disaggregates	44,047	
PMTCT_ARV_TA	PMTCT_ARV_TA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for	93 %	



	mother-to-child-transmission (MTCT) during pregnancy and delivery (TA)		
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	36,718	
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	39,482	
	Life-long ART (including Option B+)	36,718	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	23,132	
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	13,586	
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
	Single-dose nevirapine (with or without tail)	0	0



	Sum of Regimen Type disaggregates	36,718	0
	Sum of New and Current disaggregates	36,718	
BS_COLL	Number of whole blood collections each year by the NBTS network	70,000	70,000
	By: Number of whole blood donations screened for HIV in an NBTS network laboratory		
	By: Number of whole blood donations screened for HIV in an NBTS network laboratory that are identified as reactive for HIV		
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	1,078	1,201
	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)		
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)		
	Sub-Disag: Surgical		



	intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)		
	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)		
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)		
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)		
	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)		
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)		
	Sub-Disag: By Medical		



	device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)		
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	85,258	60,070
	By Age: <1	0	0
	By Age: 1-9	0	0
	By Age: 10-14	23,070	17,860
	By Age: 15-19	24,816	16,725
	By Age: 20-24	20,053	13,249
	By Age: 25-29		
	By Age: 30-49		
	By Age: 50+	1,465	2,023
	Sum of age disaggregates	85,258	60,070
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)		
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)		
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site		
	By circumcision technique: Surgical VMMC		



	By circumcision technique: Device-based VMMC		
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery		
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery		
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	85,258	
	By Age: <1	0	
	By Age: 1-9	0	
	By Age: 10-14	23,070	
	By Age: 15-19	24,816	
	By Age: 20-24	20,053	
	By Age: 25-49	15,854	
	By Age: 50+	1,465	
	Sum of Age disaggregates	85,258	
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)		
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)		



	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site		
	By circumcision technique: Surgical VMMC		
	By circumcision technique: Device-based VMMC		
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery		
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery		
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period		
	By Age: <1		
	By Age: 1-9		
	By Age: 10-14		
	By Age: 15-19		
	By Age: 20-24		
	By Age: 25-29		
	By Age: 30-49		
By Age: 50+			



	Sum of Age disaggregations		
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)		
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)		
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site		
	By circumcision technique: Surgical VMMC		
	By circumcision technique: Device-based VMMC		
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery		
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery		
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	64 %	



	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	236,950	185,808
	Total number of people in the target population	370,932	290,325
	Age/sex: 10-14 Male	2,105	1,649
	Age/sex: 15-19 Male	27,451	21,525
	Age/sex: 20-24 Male	38,207	29,959
	Age/sex: 25-49 Male	49,499	38,814
	Age/sex: 50+ Male	8,450	6,625
	Age/sex: 10-14 Female	1,966	1,540
	Age/sex: 15-19 Female	18,892	14,814
	Age/sex: 20-24 Female	36,392	28,535
	Age/sex: 25-49 Female	45,485	35,666
	Age/sex: 50+ Female	8,503	6,681
	Sum of Age/Sex disaggregates	236,950	185,808
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	64 %	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	68,750	19,500
	Total number of people in the	107,423	30,469



	target population		
	Age/sex: 10-14 Male	611	1,234
	Age/sex: 15-19 Male	7,965	2,746
	Age/sex: 20-24 Male	11,086	2,318
	Age/sex: 25-49 Male	14,362	4,231
	Age/sex: 50+ Male	2,451	
	Age/sex: 10-14 Female	571	1,050
	Age/sex: 15-19 Female	5,482	2,343
	Age/sex: 20-24 Female	10,559	1,970
	Age/sex: 25-49 Female	13,197	3,608
	Age/sex: 50+ Female	2,466	
	Sum of Age/Sex disaggregates	68,750	19,500
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	9,100	13,739
	Total estimated number of key population in the catchment area		
	By key population type: Female sex workers (FSW) (Numerator: Number of key	8,000	7,776



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,100	5,963



	<p>By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>0</p>	
	<p>By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)</p>		
	<p>By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)</p>		
	<p>By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)</p>		
	<p>By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)</p>		



	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	436,496	1,783,719
	By Test Result: Negative		1,599,849
	By Test Result: Positive		183,870
	Sum of Test Result disaggregates		1,783,719
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex: Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		
	Test Result by Age and Sex: Positive: <1 Female		



	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex: Positive: 15-19 Female		
	Test Result by Age and Sex: Positive: 20-24 Female		
	Test Result by Age and Sex: Positive: 25-49 Female		
	Test Result by Age and Sex: Positive: 50+ Female		
	Test Result by Age and Sex: Negative: <1 Male		
	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex: Negative: 15-19 Male		
	Test Result by Age and Sex: Negative: 20-24 Male		
	Test Result by Age and Sex: Negative: 25-49 Male		
	Test Result by Age and Sex: Negative: 50+ Male		
	Test Result by Age and Sex: Negative: <1 Female		
	Test Result by Age and Sex: Negative: 1-4 Female		



	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		
	Test Result by Age and Sex: Negative: 15-19 Female		
	Test Result by Age and Sex: Negative: 20-24 Female		
	Test Result by Age and Sex: Negative: 25-49 Female		
	Test Result by Age and Sex: Negative: 50+ Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	13,411	134,230
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	133,006	576,544
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	19,487	107,884
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	270,592	965,061
	Sum of Aggregated Age/Sex <15	32,898	242,114
	Sum of Aggregated Age/Sex 15+	403,598	1,541,605
	Sum of Aggregated Age/Sex disaggregates	436,496	1,783,719
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by		



	Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All results		



	Service Delivery Point by Result: Tuberculosis - Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		
	Service Delivery Point by Result: Outpatient Department - Negative		
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		
	Service Delivery Point by		



	Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive		



	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months		
	By Test Result: Negative		
	By Test Result: Positive		
	Sum of Test Result disaggregates		



	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Sum of Age/Sex disaggregates		
	Aggregated Age/sex: <15 Male		
	Aggregated Age/sex: 15+ Male		
	Aggregated Age/sex: <15 Female		
	Aggregated Age/sex: 15+ Female		
	Sum of Aggregated Age/Sex <15		
	Sum of Aggregated Age/Sex 15+		
	Sum of Aggregated Age/Sex disaggregates		
HTC_TST_NGI	Number of individuals who	1,867,498	



	received T&C services for HIV and received their test results during the past 12 months		
	By Test Result: Negative		
	By Test Result: Positive		
	Sum of Test Result disaggregates		
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Sum of Age/Sex disaggregates		
	Aggregated Age/sex: <15 Male	57,807	
	Aggregated Age/sex: 15+ Male	573,292	
	Aggregated Age/sex: <15 Female	83,990	
	Aggregated Age/sex: 15+	1,166,321	



	Female		
	Sum of Aggregated Age/Sex <15	141,797	
	Sum of Aggregated Age/Sex 15+	1,739,613	
	Sum of Aggregated Age/Sex disaggregates	1,881,410	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,431,002	0
	By Test Result: Negative		0
	By Test Result: Positive		0
	Sum of Test Result disaggregates		0
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
	Test Result by Age and Sex: Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		
	Test Result by Age and Sex: Positive: <1 Female		



	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		
	Test Result by Age and Sex: Positive: 15-19 Female		
	Test Result by Age and Sex: Positive: 20-24 Female		
	Test Result by Age and Sex: Positive: 25-49 Female		
	Test Result by Age and Sex: Positive: 50+ Female		
	Test Result by Age and Sex: Negative: <1 Male		
	Test Result by Age and Sex: Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		
	Test Result by Age and Sex: Negative: 15-19 Male		
	Test Result by Age and Sex: Negative: 20-24 Male		
	Test Result by Age and Sex: Negative: 25-49 Male		
	Test Result by Age and Sex: Negative: 50+ Male		
	Test Result by Age and Sex: Negative: <1 Female		
	Test Result by Age and Sex: Negative: 1-4 Female		



	Test Result by Age and Sex: Negative: 5-9 Female		
	Test Result by Age and Sex: Negative: 10-14 Female		
	Test Result by Age and Sex: Negative: 15-19 Female		
	Test Result by Age and Sex: Negative: 20-24 Female		
	Test Result by Age and Sex: Negative: 25-49 Female		
	Test Result by Age and Sex: Negative: 50+ Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	43,968	0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	436,046	0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	63,883	0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	887,105	0
	Sum of Aggregated Age/Sex <15	107,851	0
	Sum of Aggregated Age/Sex 15+	1,323,151	0
	Sum of Aggregated Age/Sex disaggregates	1,431,002	0
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by		



	Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All results		



	Service Delivery Point by Result: Tuberculosis - Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		
	Service Delivery Point by Result: Outpatient Department - Negative		
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		
	Service Delivery Point by		



	Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - All		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Positive		
	Service Delivery Point by		



	Result: Voluntary Counseling & Testing (standalone) - Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria		0
	Age/Sex: <10 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20-24 Male		
	Age/Sex: 25+ Male		
	Age/Sex: <10 Female		



	Age/Sex: 10-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20-24 Female		
	Age/Sex: 25+ Female		
	By Age: 0-9		
	By Age: 10-14		
	By Age: 15-19		
	By Age: 20-24		
	By Age: 25+		
	Sum of Age disaggregates		
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	287,442	310,400
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	By: Age/sex: Male 18-24		
	By: Age/sex: Male 25+		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	By: Age/sex: 18-24 Female		
	By: Age/sex: 25+ Female		
	Sum of Age/Sex disaggregates		
	Required only for DREAMS countries - By service, age		



	and sex: Education Support Female <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+		
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 1-4		
	Required only for DREAMS		



	countries - By service, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14		



	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver		



	Programs Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries - By service, age		



	and sex: Social Protection Male <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS		



	countries - By service, age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14		



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+		
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	33,300	700
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	By age/sex: 18-24 Male		
	By age/sex: 25+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	By age/sex: 18-24 Female		
	By age/sex: 25+ Female		
	Sum of Age/Sex disaggregates		
Required only for DREAMS			



	countries: By Service Area, age and sex: Education Support Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 1-4		



	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9		



	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9		
	Required only for DREAMS		



	countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14		



	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social		



	Protection Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries: By Service Area,		



	age and sex: Economic Strengthening Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4		
	Required only for DREAMS		



	countries: By Service Area, age and sex: Other Service Areas Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+		
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	245,486	
	By Age/Sex: <15 Female	13,391	
	By Age/Sex: <15 Male	12,255	
	By Age/Sex: 15+ Female	140,359	
	By Age/Sex: 15+ Male	79,481	
	Sum of Age/Sex disaggregates	245,486	
	By Age: <15	25,647	
	By Age: 15+	219,839	
	Sum of Age disaggregates	245,486	
	By Sex: Female	153,750	
By Sex: Male	91,736		



	Sum of Sex disaggregates	245,486	
C2.1.D_NA	Number of HIV-positive individuals receiving a minimum of one clinical service		
	By Age/Sex: <15 Female		
	By Age/Sex: <15 Male		
	By Age/Sex: 15+ Female		
	By Age/Sex: 15+ Male		
	Sum of Age/Sex disaggregates		
	By Age: <15		
	By Age: 15+		
	Sum of Age disaggregates		
	By Sex: Female		
	By Sex: Male		
	Sum of Sex disaggregates		
	C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	602,067
By Age/Sex: <15 Female		32,843	
By Age/Sex: <15 Male		30,057	
By Age/Sex: 15+ Female		344,237	
By Age/Sex: 15+ Male		194,930	
Sum of Age/Sex disaggregates		602,067	
By Age: <15		62,900	
By Age: 15+		539,167	
Sum of Age disaggregates		602,067	
By Sex: Female		377,080	
By Sex: Male		224,987	
Sum of Sex disaggregates		602,067	



C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	493,461	
	By Age/Sex: <15 Female	26,918	
	By Age/Sex: <15 Male	24,635	
	By Age/Sex: 15+ Female	282,141	
	By Age/Sex: 15+ Male	159,767	
	Sum of Age/Sex disaggregates	493,461	
	By Age: <15	51,553	
	By Age: 15+	441,908	
	Sum of Age disaggregates	493,461	
	By Sex: Female	279,059	
	By Sex: Male	184,402	
	Sum of Sex disaggregates	463,461	
C2.4.D_DSD	C2.4.D_DSD TB/HIV: Percent of HIV-positive patients who were screened for TB in HIV care or treatment setting	99 %	
	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	243,031	
	Number of HIV-positive individuals receiving a minimum of one clinical service	245,486	
C2.5.D_DSD	C2.5.D_DSD Percent of HIV-positive patients in HIV care or treatment (pre-ART or ART) who started TB treatment	n/a	



	Number of HIV-positive patients in HIV care who started TB treatment		
	Number of HIV-positive individuals receiving a minimum of one clinical service	245,486	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		463,312
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Sun of Age/Sex disaggregates		
	Aggregated Age/sex - USE WITH HQ PERMISSION		23,165



	ONLY: <15 Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		157,525
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		23,165
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		259,457
	Sum of Aggregated Age/Sex disaggregates		463,312
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
Age/sex: 25-49 Female			



	Age/sex: 50+ Female		
	Sum of Age/Sex disaggregates		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates		
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		282,379
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		



	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Sum of Age/sex disaggregates		
	Aggregated Age/sex: <15 Male		14,119
	Aggregated Age/sex: 15+ Male		96,010
	Aggregated Age/sex: <15 Female		14,121
	Aggregated Age/sex: 15+ Female		158,129
	Sum of Aggregated Age/sex disaggregates		282,379
CARE_SITE	CARE_SITE Percentage of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	n/a	
	Number of PEPFAR-supported HIV clinical care sites at which at		389



	<p>least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole</p>		
	<p>Total number of PEPFAR supported sites providing clinical care services</p>		389
	<p>By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole</p>		389
	<p>By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND</p>		



	3) if eligible, cotrimoxazole		
	Sum of Numerator Site Support Type disaggregates		389
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services		389
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services		
	Sum of Denominator Site Support Type disaggregates		389
FN_SITE	FN_SITE Percentage of PEPFAR-supported sites achieving 90% of nutrition assessments that result in an accurate categorization of malnutrition	n/a	
	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition		3
	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services		3
	By site support type: Direct Service Delivery (DSD):		2



	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition		
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition		0
	Sum of Numerator Support Type disaggregates		2
	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services		2
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services		1
	Sum of Denominator Support Type disaggregates		3
FN_THER_DSD	FN_THER_DSD Proportion of clinically undernourished PLHIV who received therapeutic or supplementary	87 %	



	food		
	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,625	1,225
	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	1,875	1,375
	Age: <1		
	Age: 1-4		
	Age: 5-14		
	Age: 15-17		
	Age: 18+		
	Sum of Age disaggregates		
	Aggregated Age: <18		
	Aggregated Age: 18+		
	Sum of Aggregated Age disaggregates		
	By Pregnancy/Postpartum Status: Pregnant		
	By Pregnancy/Postpartum Status: Postpartum		
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period		9,147



	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period		9,628
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Male		
	Female		
	Sum of Sex disaggregates		
	Newly tested		
	Known HIV-positive		
	Sum of Test Status disaggregates		
	Aggregated Age: <15		
	Aggregated Age: 15+		
	Sum of Aggregated Age disaggregates		
	Timeliness: Art initiation <8 weeks of start of TB treatment		
	Timeliness: Art initiation >8 weeks of start of TB treatment		
TB_ARTSITE	TB_ARTSITE Proportion of PEPFAR-supported TB basic management units at which 80% of registered TB cases	n/a	



	who are HIV-positive are on ART		
	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period		130
	The number of PEPFAR-supported TB basic management units		130
	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period		130
	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period		0
	Sum of Numerator Site Support Type disaggregates		130
	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic		130



	management units		
	By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units		0
	Sum of Denominator Site Support Type disaggregates		130
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		458,679
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		463,312
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Aggregated Age - USE WITH HQ PERMISSION ONLY:		



	<15		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		
	Sum of Aggregated Age disaggregates		
	Sex: Male		
	Sex: Female		
	Sum of Sex disaggregates		
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	45 %	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,891	22,211
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	10,869	44,421
	By infants who received a virologic test within 2 months of birth		
	By infants who received their first virologic HIV test between 2 and 12 months of age		
	Sum of Infant Age disaggregates		
	By infants with a positive virologic test result within 12		



	months of birth		
	Number of infants with a positive virological test result within 2 months of birth		
	Number of infants with a positive virological test result within 12 months of birth		
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	118,562	469,189
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Aggregated Age/Sex: <1 Male	1,073	1,172
	Aggregated Age/Sex: <1 Female	1,553	1,172
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	36,474	147,807
	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female	70,179	274,502
	Sum of Aggregated Age/Sex <15	11,909	46,880



	Sum of Aggregated Age/Sex 15+	106,653	422,309
	Sum of Aggregated Age/Sex disaggregates	118,562	469,189
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	490,555	
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15+ Female		
	Sum of Age/Sex disaggregates		
	Aggregated Age/Sex: <1 Male	4,440	
	Aggregated Age/Sex: <1 Female	6,426	
	Aggregated Age/Sex: <15 Male	20,509	
	Aggregated Age/Sex: 15+ Male	150,911	
	Aggregated Age/Sex: <15 Female	28,764	
	Aggregated Age/Sex: 15+ Female	290,371	
	Sum of Aggregated Age/Sex disaggregates	490,555	
Sum of Aggregated Age/Sex <15	49,273		
Sum of Aggregated Age/Sex	441,282		



	15+		
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	371,993	
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Sum of Age/Sex disaggregations		
	Aggregated Age/Sex: <1 Male	3,367	
	Aggregated Age/Sex: <1 Female	4,873	
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	114,437	
	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female	220,192	
	Sum of Aggregated Age/Sex <15	37,364	
	Sum of Aggregated Age/Sex 15+	334,629	
Sum of Aggregated Age/Sex	371,993		



	disaggregates		
TX_DIST	TX_DIST Percentage of Districts that are PEPFAR supported with documented routine supportive supervision visits to 75% of ART sites in District	n/a	
	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District		28
	Total number of PEPFAR supported District Health Offices		28
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	28,460	128,790
	By Age/Sex: <1 Male		725
	By Age/Sex: 1-4 Male		4,340
	By Age/Sex: 5-9 Male		1,449
	By Age/Sex: 10-14 Male		725
	By Age/Sex: 15-19 Male		10,044
	By Age/Sex: 20-24 Male		10,044
	By Age/Sex: 25-49 Male		18,069
	By Age/Sex: 50+ Male		2,820
	By Age/Sex: <1 Female		725
	By Age/Sex: 1-4 Female		4,340
	By Age/Sex: 5-9 Female		1,449
	By Age/Sex: 10-14 Female		2,455
	By Age/Sex: 15-19 Female		18,542
By Age/Sex: 20-24 Female		18,542	
By Age/Sex: 25-49 Female		33,362	



	By Age/Sex: 50+ Female		2,895
	Sum of Age/Sex disaggregates		130,526
	Aggregated Grouping by Age: <1 Male	135	725
	Aggregated Grouping by Age/Sex: 1-14 Male		
	Aggregated Grouping by Age/Sex: 15+ Male	7,654	40,977
	Aggregated Grouping by Age/Sex: <1 Female	213	725
	Aggregated Grouping by Age/Sex: 1-14 Female		
	Aggregated Grouping by Age/Sex: 15+ Female	18,415	73,341
	Sum of Aggregated Age/Sex disaggregates	28,460	128,790
	Pregnancy status	8,937	27,012
	Breastfeeding status	1,056	5,692
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	81 %	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	17,440	100,177
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost	21,531	122,165



	to follow-up		
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		



	ART)		
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who		



	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost		



	to follow-up)		
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Numerator by Status: Pregnant		
	Numerator by Status: Breastfeeding		
	Denominator by Status: Pregnant		
	Denominator by Status: Breastfeeding		
TX_SITE	TX_SITE Percentage of PEPFAR-supported ART sites achieving a 75% ART retention rate	n/a	
	Number of PEPFAR-supported ART		385



	sites with a retention rate of 75% or greater for patients 12 months after ART initiation		
	Total number of PEPFAR-supported ART sites		385
	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation		385
	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation		
	Sum of Numerator Site Support Type disaggregates		385
	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites		385
	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites		0
	Sum of Denominator Site		385



	Support Type disaggregates		
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	21	21
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	151	223
	By clinical laboratories		
	By Point-of-care testing sites		
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program		
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing		
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program		
	HIV serologic/diagnostic testing: Number of		



	laboratories that achieve acceptable successful passing criteria in this PT program		
	CD4: Number of laboratories that perform this testing		
	CD4: Number of laboratories that participate in this PT program		
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	Early infant diagnostics: Number of laboratories that perform this testing		
	Early infant diagnostics: Number of laboratories that participate in this PT program		
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	HIV viral load: Number of laboratories that perform this testing		
	HIV viral load: Number of laboratories that participate in this PT program		
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT		



	program		
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing		
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		
	TB diagnostics (Culture/DST): Number of		



	laboratories that participate in this PT program		
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program		
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	64	224
	By Graduates: Doctors		
	By Graduates: Nurses		
	By Graduates: Midwives		
	By Graduates: Social service workers		
	By Graduates: Laboratory professionals		
	By Graduates: Other		
	Sum of Graduates disaggreagtes		
SC_TRAIN	SC_TRAIN Percentage of individuals who received competency-based, certificate, or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	n/a	



	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities		1,764
	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities		1,820
	By: Individuals trained in a nationally- or internationally-recognized pre-service training program		
	By: Individuals who passed a competency-based training to conduct supply chain activities		
	By: Individuals who passed a competency-based training to perform inventory management		
	By: Individuals who passed a competency-based training to develop distribution plans		
	By: Individuals who passed a competency-based training to perform supportive supervision		
	By: Individuals who passed a competency-based training to perform quantification		



FPINT_SITE_DSD	FPINT_SITE_DSD Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services	n/a	
	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services		347
	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment		355
	Service delivery type: Care and Support		
	Service delivery type: Treatment		
	Service delivery type: PMTCT		
	Sum of Service delivery type (Care, Tx and PMTCT) disaggregates		
	QI_SITE	QI_SITE Percentage of PEPFAR-supported clinical service sites with quality improvement activities implemented that address clinical HIV program processes or outcomes and have documented process results in the last 6 months	n/a



	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months		389
	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC		389
	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months		389
	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months		0
	Sum of Numerator Site Support Type disaggregates		389



	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC		389
	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC		0
	Sum of Denominator Site Support Type disaggregates		389
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model		



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7166	Howard University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,000,000
9266	John Snow, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	2,330,895
9276	National AIDS Commission, Malawi	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	507,892
9281	University of Washington	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	5,198,799
9882	Johns Hopkins University Bloomberg School of Public Health	University	U.S. Agency for International Development	GHP-State	0



9883	Population Services International	NGO	U.S. Agency for International Development	GHP-State	1,200,000
10427	Malawi Blood Transfusion Service	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,760,868
11453	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	77,145
12105	Dignitas International	NGO	U.S. Agency for International Development	GHP-State	5,281,612
12107	Partners in Hope	FBO	U.S. Agency for International Development	GHP-State, GHP-USAID	4,989,322
12109	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	1,100,000
12110	University of Malawi College of Medicine	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,000,000
12111	Ministry of Health, Malawi	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,704,088



12116	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	75,000
12118	Banja La Mtsogolo	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	1,000,000
12119	Global AIDS Interfaith Alliance	FBO	U.S. Agency for International Development	GHP-State	389,982
12126	Feed the Children	NGO	U.S. Agency for International Development	GHP-State	790,000
12130	Baylor College of Medicine Children's Foundation	University	U.S. Agency for International Development	GHP-State, GHP-USAID	5,727,630
12131	Christian Health Association of Malawi	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,100,000
12638	JHPIEGO	University	U.S. Agency for International Development	GHP-USAID	4,250,829
13101	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-USAID	500,000
14113	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	2,888,536



			Prevention		
14242	FHI 360	NGO	U.S. Agency for International Development	GHP-State	400,000
14246	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	720,000
14249	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State, GHP-USAID	0
14432	JHPIEGO	University	U.S. Department of Defense	GHP-State	450,000
14441	Lighthouse	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,703,563
14442	BAOBAB Health Partnership	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,805,000
14443	United Nations Children's Fund	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14448	Partnership for Supply Chain	Private Contractor	U.S. Agency for International	GHP-State	0



	Management		Development		
15888	UNICEF	Multi-lateral Agency	U.S. Agency for International Development	GHP-State, GHP-USAID	800,000
16485	TBD	TBD	Redacted	Redacted	Redacted
16486	TBD	TBD	Redacted	Redacted	Redacted
16487	Futures Group	Private Contractor	U.S. Agency for International Development	GHP-State	400,000
16625	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	1,805,000
16678	Management Sciences for Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,875,000
16704	TBD	TBD	Redacted	Redacted	Redacted
16716	TBD	TBD	Redacted	Redacted	Redacted
16794	JHPIEGO	University	U.S. Agency for International Development	GHP-State	1,641,250
17097	Project Concern International	NGO	U.S. Department of Defense	GHP-State	1,580,000
17268	Columbia University	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	0
17341	TBD	TBD	Redacted	Redacted	Redacted



17451	TBD	TBD	Redacted	Redacted	Redacted
17480	TBD	TBD	Redacted	Redacted	Redacted
17487	TBD	TBD	Redacted	Redacted	Redacted
17488	University of Malawi College of Medicine	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	500,000
17489	TBD	TBD	Redacted	Redacted	Redacted
17585	TBD	TBD	Redacted	Redacted	Redacted
17590	TBD	TBD	Redacted	Redacted	Redacted
17593	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	0
17594	TBD	TBD	Redacted	Redacted	Redacted
17720	VISTA PARTNERS	Implementing Agency	U.S. Department of Defense	GHP-State	150,000



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 17720</b>	<b>Mechanism Name: Military Electronic Health Information Network</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: VISTA PARTNERS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 150,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	150,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

Military Population

### Budget Code Information

<b>Mechanism ID: 17720</b>
----------------------------



<b>Mechanism Name:</b>	<b>Military Electronic Health Information Network</b>		
<b>Prime Partner Name:</b>	<b>VISTA PARTNERS</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	150,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 17594</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 17593</b>	<b>Mechanism Name: DHS 7</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17593 <b>Mechanism Name:</b> DHS 7 <b>Prime Partner Name:</b> Abt Associates			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 17590</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 17585</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	



## Implementing Mechanism Details

<b>Mechanism ID: 17489</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

## Implementing Mechanism Details

<b>Mechanism ID: 17488</b>	<b>Mechanism Name: Improving Medical Education in Malawi</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Malawi College of Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 500,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	500,000

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

Human Resources for Health	500,000
----------------------------	---------

## Key Issues

End-of-Program Evaluation



**Budget Code Information**

<b>Mechanism ID:</b> 17488			
<b>Mechanism Name:</b> Improving Medical Education in Malawi			
<b>Prime Partner Name:</b> University of Malawi College of Medicine			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	100,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17487	<b>TBD:</b> Yes
REDACTED	

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17480	<b>TBD:</b> Yes
REDACTED	

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17451	<b>TBD:</b> Yes
REDACTED	

**Implementing Mechanism Details**

Approved



<b>Mechanism ID: 17341</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 17268</b>	<b>Mechanism Name: Global HIV/AIDS Nursing Initiative</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 1</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information



<b>Mechanism ID:</b> 17268			
<b>Mechanism Name:</b> Global HIV/AIDS Nursing Initiative			
<b>Prime Partner Name:</b> Columbia University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	3	3	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	460	475	Redacted
HRH_PRE	By Graduates: Nurses	460	475	Redacted
HRH_PRE	Sum of Graduates disaggregated	460	475	Redacted
HRH_PRE	By new graduates who are licensed and registered: Nurses	460	475	Redacted

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17097	<b>Mechanism Name:</b> DOD Support to Malawi Defense Force HIV AIDS Program
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Project Concern International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 1,580,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,580,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	200,000
Condom programming	100,000
Gender: GBV	40,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	40,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building

### Key Issues

Military Population

TB

Workplace Programs

Family Planning



**Budget Code Information**

<b>Mechanism ID:</b> 17097			
<b>Mechanism Name:</b> DOD Support to Malawi Defense Force HIV AIDS Program			
<b>Prime Partner Name:</b> Project Concern International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	90,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	90,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	300,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	100,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	2,500
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	0	5,000
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	0	8,500
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,357	2,755
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,834	3,835
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	433	433
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	12	6
TX_SITE	Total number of PEPFAR-supported ART sites	12	6
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	6	6
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART	6	



	initiation		
TX_SITE	Sum of Numerator Site Support Type disaggregates	12	6
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	6	6
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	6	
TX_SITE	Sum of Denominator Site Support Type disaggregates	12	6
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	8	6
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	8	6
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	0
LAB_CAP_DSD	Sum of Site Support Type disaggregates	8	6
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,357	2,755

### Implementing Mechanism Details

<b>Mechanism ID: 16794</b>	<b>Mechanism Name: MCHIP/SANJHANI</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,641,250</b>	<b>Total Mechanism Pipeline: Redacted</b>
---	---



<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,641,250

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	210,875
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Focus Area:	Equity in HIV prevention, care, treatment and support
Condom programming	210,875

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16794		
<b>Mechanism Name:</b>	MCHIP/SANJHANI		
<b>Prime Partner Name:</b>	JHPIEGO		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	1,641,250	0

### Implementing Mechanism Indicator Information



Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	5	5
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	6	6
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery	0	0



	(DSD)		
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	416	369
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	24,000	18,441
VMMC_CIRC_DSD	By Age: <1	0	0
VMMC_CIRC_DSD	By Age: 1-9	0	0
VMMC_CIRC_DSD	By Age: 10-14	11,283	5,484
VMMC_CIRC_DSD	By Age: 15-19	6,961	5,135
VMMC_CIRC_DSD	By Age: 20-24	2,639	4,068
VMMC_CIRC_DSD	By Age: 25-49	2,878	3,136
VMMC_CIRC_DSD	By Age: 50+	239	618
VMMC_CIRC_DSD	Sum of age disaggregates	24,000	18,441
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	24,000	
VMMC_CIRC_NGI	By Age: <1	0	
VMMC_CIRC_NGI	By Age: 1-9	0	
VMMC_CIRC_NGI	By Age: 10-14	11,283	



VMMC_CIRC_NGI	By Age: 15-19	6,961	
VMMC_CIRC_NGI	By Age: 20-24	2,639	
VMMC_CIRC_NGI	By Age: 25-49	2,878	
VMMC_CIRC_NGI	By Age: 50+	239	
VMMC_CIRC_NGI	Sum of Age disaggregates	24,000	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,567	17,518
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	10,158	5,255
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,409	12,263
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	10,158	5,255
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	9,409	12,263
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	19,567	17,518
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,567	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	10,158	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	9,409	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	10,158	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	9,409	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	19,567	

**Implementing Mechanism Details**

<b>Mechanism ID: 16716</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 16704</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	



### Implementing Mechanism Details

<b>Mechanism ID: 16678</b>	<b>Mechanism Name: District Health System Strengthening and Quality Improvement for Service Delivery in Malawi under PEPFAR</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,875,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,875,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
Motor Vehicles: Purchased	50,000

### Key Issues

Child Survival Activities

Safe Motherhood

TB



**Budget Code Information**

<b>Mechanism ID:</b>	16678		
<b>Mechanism Name:</b>	District Health System Strengthening and Quality Improvement for		
<b>Prime Partner Name:</b>	Service Delivery in Malawi under PEPFAR Management Sciences for Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	454,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	124,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	354,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	62,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	60,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	47,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	600,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,018,497	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	155,503	0



## Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	144	80	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	144	80	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	0	80	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	133	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	0	80	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	140	78	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	78	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	109	78	Redacted



SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	0	78	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	140	78	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of	8,294	9,218	Redacted



	mother-to-child-transmission (MTCT) during pregnancy and delivery			
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	9,758	10,241	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	8,294	9,218	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	5,057	5,623	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,240	3,597	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	8,294	9,218	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	8,297	9,220	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	8,294	9,218	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	9,758	10,241	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	8,294	9,218	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	5,057	5,623	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,240	3,597	Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	8,294	9,218	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	8,297	9,220	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their	76,897	80,048	Redacted



	results)			
PMTCT_STAT_NG I	Number of new ANC and L&D clients	93,778	94,168	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	3,845	4,002	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	6,158	6,404	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	10,003	10,406	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	76,897	80,048	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	93,778	94,168	Redacted
PMTCT_STAT_TA	By: Known positives at entry	3,845	4,002	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	6,158	6,404	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	10,003	10,406	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0	0	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the	0	0	Redacted



	minimum standards required)			
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	374,400	645,230	Redacted
HTC_TST_NGI	By Test Result: Negative	329,472	567,802	Redacted
HTC_TST_NGI	By Test Result: Positive	44,928	77,428	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	374,400	645,230	Redacted
HTC_TST_NGI	Age/sex: <1 Male	2,471	4,258	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	11,120	19,164	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	14,826	25,551	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	17,297	29,809	Redacted



HTC_TST_NGI	Age/sex: 15-19 Male	28,417	48,973	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	33,359	57,490	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	14,826	25,551	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	1,236	2,130	Redacted
HTC_TST_NGI	Age/sex: <1 Female	5,017	8,646	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	22,576	38,908	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	30,102	51,877	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	35,119	60,522	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	57,695	99,430	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	67,729	116,721	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	30,102	51,877	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	2,508	4,324	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	374,400	645,231	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	45,714	78,782	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	77,838	134,144	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	92,814	159,953	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	158,034	272,352	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	138,528	238,735	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	235,872	406,496	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	374,400	645,231	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	374,400	449,280	Redacted
HTC_TST_TA	By Test Result: Negative	329,472	395,366	Redacted
HTC_TST_TA	By Test Result: Positive	44,928	53,914	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	374,400	449,280	Redacted
HTC_TST_TA	Age/sex: <1 Male	2,471	2,965	Redacted
HTC_TST_TA	Age/sex: 1-4 Male	11,120	13,344	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	14,826	17,792	Redacted
HTC_TST_TA	Age/sex: 10-14 Male	17,297	20,756	Redacted
HTC_TST_TA	Age/sex: 15-19 Male	28,417	34,100	Redacted



HTC_TST_TA	Age/sex: 20-24 Male	33,359	40,031	Redacted
HTC_TST_TA	Age/sex: 25-49 Male	14,826	17,792	Redacted
HTC_TST_TA	Age/sex: 50+ Male	1,236	1,483	Redacted
HTC_TST_TA	Age/sex: <1 Female	5,017	6,020	Redacted
HTC_TST_TA	Age/sex: 1-4 Female	22,576	27,092	Redacted
HTC_TST_TA	Age/sex: 5-9 Female	30,102	36,122	Redacted
HTC_TST_TA	Age/sex: 10-14 Female	35,119	42,142	Redacted
HTC_TST_TA	Age/sex: 15-19 Female	57,695	69,234	Redacted
HTC_TST_TA	Age/sex: 20-24 Female	67,729	81,274	Redacted
HTC_TST_TA	Age/sex: 25-49 Female	30,102	36,122	Redacted
HTC_TST_TA	Age/sex: 50+ Female	2,508	3,011	Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	374,400	449,280	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	45,714	54,857	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	77,838	93,406	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	92,814	111,376	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	158,034	189,641	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	138,528	166,233	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	235,872	283,047	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	374,400	449,280	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	174,491		Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	6,441		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	10,179		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	97,116		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	60,755		Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	174,491		Redacted
C2.1.D_NGI	By Age: <15	16,620		Redacted

C2.1.D_NGI	By Age: 15+	157,871		Redacted
C2.1.D_NGI	Sum of Age disaggregates	174,491		Redacted
C2.1.D_NGI	By Sex: Female	103,557		Redacted
C2.1.D_NGI	By Sex: Male	70,934		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	174,491		Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	174,491		Redacted
C2.1.D_TA	By Age/Sex: <15 Female	6,441		Redacted
C2.1.D_TA	By Age/Sex: <15 Male	10,179		Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	97,116		Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	60,755		Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	174,491		Redacted
C2.1.D_TA	By Age: <15	16,620		Redacted
C2.1.D_TA	By Age: 15+	157,871		Redacted
C2.1.D_TA	Sum of Age disaggregates	174,491		Redacted
C2.1.D_TA	By Sex: Female	103,557		Redacted
C2.1.D_TA	By Sex: Male	70,934		Redacted
C2.1.D_TA	Sum of Sex disaggregates	174,491		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	159,624	1	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	1,729	30	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	174,491	199,519	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	10,179	11,708	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	60,755	7,404	Redacted



CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,441	69,867	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	97,116	110,540	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	174,491	199,519	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	41,934	55,015	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	1,083	2,751	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,975	18,704	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	13,738	2,751	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	25,138	30,809	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	41,934	55,015	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,823	5,207	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	9,099	10,415	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,581		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,242		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,823		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	41		Redacted
TX_CURR_NGI	Number of adults and children receiving	147,784	165,526	Redacted



	antiretroviral therapy (ART)			
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	1,095	1,233	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	2,011	2,250	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	3,809	4,273	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	6,791	54,241	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	48,428	7,805	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	88,576	99,207	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	147,604	165,526	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	52,237	12,078	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	95,367	153,448	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	147,784	165,526	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	1,095	1,233	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	2,011	2,250	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	3,809	4,273	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	6,791	54,241	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	48,428	7,805	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	88,576	99,207	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	52,237	12,078	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	95,367	153,448	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	147,604	165,526	Redacted
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District	7	7	Redacted
TX_DIST	Total number of PEPFAR supported District Health Offices	7	7	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	28,490	25,251	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	201	166	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15	731	1,659	Redacted

	Male			
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	9,329	7,841	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	390	166	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,347	1,659	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	17,083	14,092	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	28,490	25,251	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	30,148	20,706	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	36,756	25,251	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	75	66	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	129	66	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	0	0	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for	75	66	Redacted



	patients 12 months after ART initiation			
TX_SITE	Sum of Numerator Site Support Type disaggregates	75	66	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	0	0	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	129	66	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	129	66	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	12	12	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	100	100	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	100	100	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	17	17	Redacted
LAB_CAP_DSD	By clinical laboratories	12	12	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	5	5	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	17	17	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	17	17	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 16625</b>	<b>Mechanism Name: Construction and Renovation</b>
Funding Agency: State/AF	Procurement Type: Contract
Prime Partner Name: Regional Procurement Support Office/Frankfurt	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,805,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,805,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Construction	1,555,000
Renovation	250,000

### Key Issues

Child Survival Activities

Safe Motherhood

TB

### Budget Code Information

<b>Mechanism ID: 16625</b>			
<b>Mechanism Name: Construction and Renovation</b>			
<b>Prime Partner Name: Regional Procurement Support Office/Frankfurt</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Approved



Governance and Systems	OHSS	1,805,000	0
------------------------	------	-----------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16487</b>	<b>Mechanism Name: Health Policy Project</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Futures Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 400,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	400,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Gender: Gender Equality	300,000

Approved



Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Motor Vehicles: Leased	15,000

### Key Issues

Family Planning

### Budget Code Information

<b>Mechanism ID:</b>	16487		
<b>Mechanism Name:</b>	Health Policy Project		
<b>Prime Partner Name:</b>	Futures Group		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	100,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

Approved



<b>Mechanism ID: 16486</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 16485</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 15888</b>	<b>Mechanism Name: Strengthening the National OVC Program</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: UNICEF	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 800,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	500,000
GHP-USAID	300,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Economic Strengthening	125,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Education	125,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Gender: GBV	200,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Gender: Gender Equality	125,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Construction	70,000

**Key Issues**

Child Survival Activities

**Budget Code Information**

<b>Mechanism ID:</b> 15888			
<b>Mechanism Name:</b> Strengthening the National OVC Program			
<b>Prime Partner Name:</b> UNICEF			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	800,000	0

**Implementing Mechanism Indicator Information**

Approved



(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14448</b>	<b>Mechanism Name: SCMS</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	<b>14448</b>
<b>Mechanism Name:</b>	<b>SCMS</b>
<b>Prime Partner Name:</b>	<b>Partnership for Supply Chain Management</b>



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 14443</b>	<b>Mechanism Name: Strengthening District Health Planning and Strategic Information to Improve Maternal and Child Health</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



## Key Issues

Child Survival Activities

### Budget Code Information

<b>Mechanism ID:</b>	14443		
<b>Mechanism Name:</b>	Strengthening District Health Planning and Strategic Information to		
<b>Prime Partner Name:</b>	Improve Maternal and Child Health		
	United Nations Children's Fund		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	28	28	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	28	28	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	42,970	42,970	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	42,970	42,970	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	42,970	42,970	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	42,970	42,970	Redacted



**Implementing Mechanism Details**

<b>Mechanism ID: 14442</b>	<b>Mechanism Name: Improving Quality of Care and Health Impact through Sustainable, Integrated, Innovative Information System Technologies in Malawi under PEPFAR</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: BAOBAB Health Partnership	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,805,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,805,000

**Sub Partner Name(s)**

Luke International Norway	University of Pittsburgh	
---------------------------	--------------------------	--

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	165,000
Motor Vehicles: Purchased	100,000

**Key Issues**

TB



**Budget Code Information**

<b>Mechanism ID:</b> 14442			
<b>Mechanism Name:</b> Improving Quality of Care and Health Impact through Sustainable, Integrated, Innovative Information System Technologies in Malawi under			
<b>Prime Partner Name:</b> PEPFAR			
BAOBAB Health Partnership			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	648,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	74,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	80,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	45,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	118,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,485,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	355,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2014	2015	Planning Budget Targets
------------------	-------	------	------	-------------------------



SITE_SUPP	Number of unique sites supported by PEPFAR	57	46	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	5	45	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	57	46	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	57	46	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	15	46	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	1	2	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	1	2	Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	195,378	211,007	Redacted
C2.1.D_TA	By Age/Sex: <15 Female	10,755	11,615	Redacted
C2.1.D_TA	By Age/Sex: <15 Male	8,768	9,470	Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	120,650	130,302	Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	55,205	59,620	Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	195,378	211,007	Redacted
C2.1.D_TA	By Age: <15	19,523	21,085	Redacted
C2.1.D_TA	By Age: 15+	175,855	189,922	Redacted
C2.1.D_TA	Sum of Age disaggregates	195,378	211,007	Redacted
C2.1.D_TA	By Sex: Female	131,405	141,917	Redacted
C2.1.D_TA	By Sex: Male	63,973	69,090	Redacted
C2.1.D_TA	Sum of Sex disaggregates	195,378	211,007	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO	180,913	189,550	Redacted

	staging) OR CD4 count OR viral load			
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,119	9,478	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,959	64,446	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	51,115	9,478	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	111,720	106,148	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	180,913	189,550	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	26,304	30,000	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	1,578	1,800	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,052	1,280	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	16,308	18,600	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	7,365	3,400	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	26,303	25,080	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	57	65	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	671	671	Redacted
CARE_SITE	By site support type: Direct Service	0	0	Redacted



	Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole			
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	57	65	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	57	65	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	0	0	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services	57	65	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	57	65	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	21,362	23,071	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented	21,362	23,071	Redacted



	HIV-positive status during TB treatment during the reporting period			
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	195,387	211,017	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	8,769	9,470	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	55,204	59,621	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	10,756	11,616	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	120,658	130,310	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	195,387	211,017	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	19,525	21,086	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	175,862	189,931	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	195,387	182,974	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	0	407	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	0	407	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	8,769	8,131	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	55,204	58,349	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	10,756	8,131	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	120,658	108,363	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	19,525	16,262	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	175,862	166,712	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	195,387	182,974	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 14441</b>	<b>Mechanism Name: Lighthouse</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Lighthouse	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: PR/SR	
G2G: Yes	Managing Agency: HHS/CDC



<b>Total All Funding Sources: 1,703,563</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,703,563

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	50,000
Motor Vehicles: Purchased	100,000

**Key Issues**

Child Survival Activities  
 TB  
 Family Planning

**Budget Code Information**

<b>Mechanism ID:</b>	14441		
<b>Mechanism Name:</b>	Lighthouse		
<b>Prime Partner Name:</b>	Lighthouse		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	90,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	10,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,533,563	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	30,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	28	12	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	9	11	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	25	12	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	2	12	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	6	11	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	2	12	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	6	11	Redacted



SITE_SUPP	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)	2	2	Redacted
SITE_SUPP	By program area/support type: Food and Nutrition Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	11	11	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	28	12	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	2	12	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: VMMC Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	0	0	Redacted

PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,600	3,259	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,700	3,389	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	1,600	3,259	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,000	1,630	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	600	1,629	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,600	3,259	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	1,600	3,259	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,450	2,500	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,500	2,550	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	2,450	2,500	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	2,450	2,500	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	850	850	Redacted



PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	900	900	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	760	760	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	90	90	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	850	850	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,400	39,823	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	0	1,593	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	117	1,796	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	117	3,389	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	40,700	40,700	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	80	80	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	1,000	1,000	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	1,080	1,080	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	39,300	39,200	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	40,500	40,400	Redacted



PMTCT_STAT_TA	By: Known positives at entry	80	80	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	750	750	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	830	830	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	42,000	105,897	Redacted
HTC_TST_DSD	By Test Result: Negative	34,500	10,590	Redacted
HTC_TST_DSD	By Test Result: Positive	7,500	95,307	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	42,000	105,897	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	420	2,575	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	20,800	35,060	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	840	2,575	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	19,940	65,687	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,260	5,150	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	40,740	100,747	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	42,000	105,897	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	138,000	138,000	Redacted
HTC_TST_NGI	By Test Result: Negative	124,100	124,100	Redacted
HTC_TST_NGI	By Test Result: Positive	13,900	13,900	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	138,000	138,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	2,900	2,900	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	56,200	56,200	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	1,900	1,900	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	77,000	77,000	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	4,800	4,800	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	133,200	133,200	Redacted

HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	138,000	138,000	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	96,000	96,000	Redacted
HTC_TST_TA	By Test Result: Negative	93,400	93,400	Redacted
HTC_TST_TA	By Test Result: Positive	2,600	2,600	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	96,000	96,000	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,400	1,400	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	31,200	31,200	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,500	1,500	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	61,900	61,900	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	2,900	2,900	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	93,100	93,100	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	96,000	96,000	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	35,000	40,308	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	600	10,706	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	600	1,019	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	20,890	24,067	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	12,910	4,516	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	35,000	40,308	Redacted
C2.1.D_DSD	By Age: <15	1,200	11,725	Redacted
C2.1.D_DSD	By Age: 15+	33,800	28,583	Redacted
C2.1.D_DSD	Sum of Age disaggregates	35,000	40,308	Redacted
C2.1.D_DSD	By Sex: Female	21,490	34,775	Redacted
C2.1.D_DSD	By Sex: Male	13,510	5,533	Redacted



C2.1.D_DSD	Sum of Sex disaggregates	35,000	40,308	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	35,000	35,000	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	600	600	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	600	600	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	20,890	20,890	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	12,910	12,910	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	35,000	35,000	Redacted
C2.1.D_NGI	By Age: <15	1,200	1,200	Redacted
C2.1.D_NGI	By Age: 15+	33,800	33,800	Redacted
C2.1.D_NGI	Sum of Age disaggregates	35,000	35,000	Redacted
C2.1.D_NGI	By Sex: Female	21,490	21,490	Redacted
C2.1.D_NGI	By Sex: Male	13,510	13,510	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	35,000	35,000	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	32,900	38,300	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	35,000	40,308	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	1,700	30	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	35,000	40,308	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	34,000	32,769	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	11		Redacted
CARE_CURR_DS	Age/sex: 1-4 Male	136		Redacted



D				
CARE_CURR_DS D	Age/sex: 5-9 Male	203		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	249		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	218		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	302		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	10,003		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	2,138		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	16		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	102		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	224		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	221		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	601		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	1,761		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	16,055		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	1,760		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	34,000		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and	7,200	18,484	Redacted



	received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_NEW_DSD	Age/sex: <1 Male	8		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	48		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	44		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	43		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	50		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	123		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	2,225		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	267		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	12		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	34		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	35		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	39		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	264		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	717		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	3,079		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	212		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	7,200		Redacted
FN_SITE	Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	2	2	Redacted
FN_SITE	Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	2	2	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	2	2	Redacted



FN_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition	0	0	Redacted
FN_SITE	Sum of Numerator Support Type disaggregates	2	2	Redacted
FN_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	2	2	Redacted
FN_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services	0	0	Redacted
FN_SITE	Sum of Denominator Support Type disaggregates	2	2	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	150	150	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	400	300	Redacted
FN_THER_DSD	Aggregated Age: <18	100	75	Redacted
FN_THER_DSD	Aggregated Age: 18+	300	225	Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	400	300	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	770	1,495	Redacted

TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	900	1,573	Redacted
TB_ART_DSD	Age: 0-4	7		Redacted
TB_ART_DSD	Age: 5-14	13		Redacted
TB_ART_DSD	Age: 15+	750		Redacted
TB_ART_DSD	Male	490		Redacted
TB_ART_DSD	Female	280		Redacted
TB_ART_DSD	Sum of Sex disaggregates	770		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	500	1,149	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,700	2,297	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	260		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	240		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	500		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	20		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	25,600	35,603	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	3	29	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	82	264	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	310	293	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	9,600	12,050	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	11	29	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	74	264	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	300	293	Redacted



TX_CURR_DSD	Age/Sex: 15+ Female	15,220	22,379	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	780	1,172	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	15,605	22,379	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	3	29	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	11	29	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	395	587	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	9,600	12,050	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	385	587	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	15,220	22,379	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	780	1,174	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	24,820	34,429	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	25,600	35,603	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	25,600	28,750	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	3	4	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	82	90	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	310	340	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	9,600	10,780	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	11	13	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	74	83	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	300	340	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	15,220	17,100	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	25,600	28,750	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,500	9,110	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	10	19	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	41	116	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	36	39	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	41	19	Redacted



TX_NEW_DSD	By Age/Sex: 15-19 Male	41	763	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	88	763	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,981	1,374	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	242	218	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	16	19	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	30	116	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	25	39	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	37	19	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	251	1,418	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	646	1,418	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,817	2,552	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	198	218	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,500	9,110	Redacted
TX_NEW_DSD	Pregnancy status	1,170	1,963	Redacted
TX_NEW_DSD	Breastfeeding status	305	547	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,500	7,471	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,200	9,110	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	50		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	72		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on	3,378		Redacted



	treatment at 12 months after initiating ART)			
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	86		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	130		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,980		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	115		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,585		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	200		Redacted



	those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,000		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	610		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,332		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	32,000	32,441	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	34,000	32,769	Redacted
TB_SCREEN_DSD	Age: <1	26		Redacted
TB_SCREEN_DSD	Age: 1-4	223		Redacted
TB_SCREEN_DSD	Age: 5-9	401		Redacted
TB_SCREEN_DSD	Age: 10-14	441		Redacted
TB_SCREEN_DSD	Age: 15-19	772		Redacted



TB_SCREEN_DSD	Age: 20-24	1,949		Redacted
TB_SCREEN_DSD	Age: 25-49	24,528		Redacted
TB_SCREEN_DSD	Age: 50+	3,660		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	1,863		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	1,050		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	30,950		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	32,000		Redacted
TB_SCREEN_DSD	Sex: Male	12,950		Redacted
TB_SCREEN_DSD	Sex: Female	19,050		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	32,000		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 14432</b>	<b>Mechanism Name: support to MDF</b>
Funding Agency: DOD	Procurement Type: Contract
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 450,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	450,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)



Human Resources for Health	105,000
Condom programming	15,000

## Key Issues

Military Population

## Budget Code Information

<b>Mechanism ID:</b> 14432 <b>Mechanism Name:</b> support to MDF <b>Prime Partner Name:</b> JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	450,000	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	99	100
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,000	5,000
VMMC_CIRC_DSD	By Age: <1	0	0
VMMC_CIRC_DSD	By Age: 1-9	0	0
VMMC_CIRC_DSD	By Age: 10-14	2,527	2,527
VMMC_CIRC_DSD	By Age: 15-19	1,228	1,228
VMMC_CIRC_DSD	By Age: 20-24	516	516



VMMC_CIRC_DSD	By Age: 25-49	696	696
VMMC_CIRC_DSD	By Age: 50+	33	33
VMMC_CIRC_DSD	Sum of age disaggregates	5,000	5,000
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,000	
VMMC_CIRC_NGI	By Age: <1	0	
VMMC_CIRC_NGI	By Age: 1-9	0	
VMMC_CIRC_NGI	By Age: 10-14	2,527	
VMMC_CIRC_NGI	By Age: 15-19	1,228	
VMMC_CIRC_NGI	By Age: 20-24	516	
VMMC_CIRC_NGI	By Age: 25-49	696	
VMMC_CIRC_NGI	By Age: 50+	33	
VMMC_CIRC_NGI	Sum of Age disaggregates	5,000	

**Implementing Mechanism Details**

<b>Mechanism ID: 14249</b>	<b>Mechanism Name: Integrated (HIV effect) Mitigation and Positive Action for Community Transformation (IMPACT)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0
GHP-USAID	0



**Sub Partner Name(s)**

Africare	Chikwawa Catholic Health Commission	Dedza Catholic Health Commission
D-Tree International	Emmanuel International	Lilongwe Catholic Health Commission
National Association of People Living with HIV/AIDS in Malawi	Opportunity International Bank of Malawi	Project Concern International
Save the Children US	World Vision International	Zomba Catholic Health Commission

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

Child Survival Activities

**Budget Code Information**

<b>Mechanism ID:</b>	14249		
<b>Mechanism Name:</b>	Integrated (HIV effect) Mitigation and Positive Action for Community Transformation (IMPACT)		
<b>Prime Partner Name:</b>	Catholic Relief Services		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	MTCT	0	0
------------	------	---	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	119,964	
OVC_SERV_DSD	Sex: Male	52,784	
OVC_SERV_DSD	Sex: Female	67,180	
OVC_SERV_DSD	Sum of Sex disaggregates	119,964	

### Implementing Mechanism Details

<b>Mechanism ID: 14246</b>	<b>Mechanism Name: Abt Associates: HPSS</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: TA	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 720,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
Funding Source	Funding Amount
GHP-State	720,000

### Sub Partner Name(s)

TBD		
-----	--	--

### Cross-Cutting Budget Attribution(s)



Human Resources for Health	640,000
Motor Vehicles: Purchased	17,885

**Key Issues**

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- End-of-Program Evaluation
- Family Planning

**Budget Code Information**

<b>Mechanism ID:</b> 14246			
<b>Mechanism Name:</b> Abt Associates: HPSS			
<b>Prime Partner Name:</b> Abt Associates			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	320,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	200,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2014	2015
TX_DIST	Number of Districts with documented routine supportive supervision visits to 75% of HIV	2	5

Approved



	care and treatment sites supported by the District		
--	--	--	--

### Implementing Mechanism Details

<b>Mechanism ID: 14242</b>	<b>Mechanism Name: FANTA III</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 400,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	400,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	400,000
---	---------

### Key Issues

Child Survival Activities

### Budget Code Information

Custom  
2015-03-30 11:53 EDT



<b>Mechanism ID:</b>	14242		
<b>Mechanism Name:</b>	FANTA III		
<b>Prime Partner Name:</b>	FHI 360		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	100,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14113</b>	<b>Mechanism Name: District Health System Strengthening and Quality Improvement for Service Delivery in Malawi under PEPFAR</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,888,536</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,888,536

### Sub Partner Name(s)

(No data provided.)



**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	36,000
----------------------------	--------

**Key Issues**

- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

**Budget Code Information**

<b>Mechanism ID:</b>	14113		
<b>Mechanism Name:</b>	District Health System Strengthening and Quality Improvement for Service Delivery in Malawi under PEPFAR		
<b>Prime Partner Name:</b>	Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	469,686	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	126,240	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	36,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	68,630	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	OHSS	60,000	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	238,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	140,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,460,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	289,980	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	151	65	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	66	65	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	85	65	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	66	65	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	85	65	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery	66	65	Redacted

	(DSD)			
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	85	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	66	65	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	85	0	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	66	65	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	85	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	16	16	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	4	4	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,875	3,849	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	3,152	4,181	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	2,875	3,849	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,639	1,924	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,236	1,925	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted

PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	2,875	3,849	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	2,875	3,849	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	4,750	5,500	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	5,253	6,000	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	4,750	5,500	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,850	3,300	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,900	2,200	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	4,750	5,500	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	4,750	5,500	Redacted

PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,875	2,150	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,101	2,300	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	1,875	2,150	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,125	1,380	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	750	770	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	1,875	2,150	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	1,875	2,150	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	83	63	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	151	63	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+	33	63	Redacted



	pregnant women			
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	50	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	83	63	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	33	63	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	50	0	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	83	63	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	51,331	80,342	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	81,481	86,290	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	1,232	1,965	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,848	2,216	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	3,080	4,181	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their	95,319	120,000	Redacted

	results)			
PMTCT_STAT_NG I	Number of new ANC and L&D clients	147,050	160,000	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	2,288	2,880	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	3,431	4,320	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	5,719	7,200	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	43,988	58,000	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	65,569	75,440	Redacted
PMTCT_STAT_TA	By: Known positives at entry	1,055	1,392	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	1,584	2,088	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	2,639	3,480	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	8,000	10,000	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,000	10,000	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	194,813	259,947	Redacted
HTC_TST_DSD	By Test Result: Negative	183,480	233,952	Redacted
HTC_TST_DSD	By Test Result: Positive	11,333	25,995	Redacted

HTC_TST_DSD	Sum of Test Result disaggregates	194,813	259,947	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,054	11,222	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	54,782	82,650	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,765	11,222	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	130,212	154,853	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	9,819	22,444	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	184,994	237,503	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	194,813	259,947	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	353,128	406,125	Redacted
HTC_TST_NGI	By Test Result: Negative	331,940	381,757	Redacted
HTC_TST_NGI	By Test Result: Positive	21,188	24,368	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	353,128	406,125	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	5,005	5,762	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	11,226	12,920	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	101,686	116,943	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	235,211	270,500	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	106,691	122,705	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	246,437	283,420	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	353,128	406,125	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	157,305	182,071	Redacted
HTC_TST_TA	By Test Result: Negative	148,154	171,147	Redacted
HTC_TST_TA	By Test Result: Positive	9,151	10,924	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	157,305	182,071	Redacted

HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,951	2,245	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,461	5,135	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	46,904	53,939	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	104,999	120,752	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	48,855	56,184	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	109,460	125,887	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	158,315	182,071	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	43,025	61,092	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	2,409	1,965	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	1,372	1,965	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	25,151	36,583	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	14,093	20,579	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	43,025	61,092	Redacted
C2.1.D_DSD	By Age: <15	1,372	3,931	Redacted
C2.1.D_DSD	By Age: 15+	39,244	57,161	Redacted
C2.1.D_DSD	Sum of Age disaggregates	40,616	61,092	Redacted
C2.1.D_DSD	By Sex: Female	27,560	38,549	Redacted
C2.1.D_DSD	By Sex: Male	15,465	22,543	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	43,025	61,092	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	64,310	70,742	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	3,535	3,889	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	1,955	2,151	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	37,970	41,767	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	20,850	22,935	Redacted

C2.1.D_NGI	Sum of Age/Sex disaggregates	64,310	70,742	Redacted
C2.1.D_NGI	By Age: <15	5,490	6,040	Redacted
C2.1.D_NGI	By Age: 15+	58,820	64,702	Redacted
C2.1.D_NGI	Sum of Age disaggregates	64,310	70,742	Redacted
C2.1.D_NGI	By Sex: Female	41,505	45,656	Redacted
C2.1.D_NGI	By Sex: Male	22,805	25,086	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	64,310	70,742	Redacted
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	21,285	23,414	Redacted
C2.1.D_TA	By Age/Sex: <15 Female	1,126	1,239	Redacted
C2.1.D_TA	By Age/Sex: <15 Male	583	641	Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	12,819	14,101	Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	6,757	7,433	Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	21,285	23,414	Redacted
C2.1.D_TA	By Age: <15	1,709	1,880	Redacted
C2.1.D_TA	By Age: 15+	19,576	21,534	Redacted
C2.1.D_TA	Sum of Age disaggregates	21,285	23,414	Redacted
C2.1.D_TA	By Sex: Female	13,945	15,340	Redacted
C2.1.D_TA	By Sex: Male	7,340	8,074	Redacted
C2.1.D_TA	Sum of Sex disaggregates	21,285	23,414	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	43,036	58,037	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	43,025	61,092	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	3,315	580	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	43,025	61,092	Redacted
CARE_CURR_DS	Number of HIV positive adults and	44,062	51,124	Redacted



D	children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,409	2,556	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	14,093	17,382	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,409	2,556	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	25,151	28,630	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	44,062	51,124	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	21,285	23,414	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	583	641	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,757	7,433	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,126	1,239	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	12,819	14,101	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	21,285	23,414	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	23,010	29,663	Redacted

CARE_NEW_DSD	Aggregated Age/sex: <15 Male	601	1,483	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	6,967	10,086	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	1,318	1,483	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	14,124	16,611	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	23,010	29,663	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	151	151	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	151	151	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	66	66	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	85	85	Redacted
CARE_SITE	Sum of Numerator Site Support Type	151	151	Redacted



	disaggregates			
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	794	2,091	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	3,152	4,181	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	119	120	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	675	1,080	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	794	1,200	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	79	120	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	43,025	53,653	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,372	2,199	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,409	17,239	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	14,093	2,199	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	25,151	32,016	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	15,465	4,398	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	27,560	49,255	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	43,025	53,653	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	64,310	70,742	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	1,955	2,151	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	20,850	22,935	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	3,535	3,889	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	37,970	41,767	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	64,310	70,742	Redacted

TX_CURR_NGI	Sum of Aggregated Age/Sex <15	5,490	6,040	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	58,820	64,702	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	21,285	23,414	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	583	641	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	6,757	7,433	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,126	1,239	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	12,819	14,101	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,709	1,880	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	19,576	21,534	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	21,285	23,414	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,580	13,290	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0	49	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	335	493	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,844	4,397	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	0	49	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	714	493	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,687	7,907	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	12,580	13,290	Redacted
TX_NEW_DSD	Pregnancy status	2,492	2,791	Redacted
TX_NEW_DSD	Breastfeeding status	150	797	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,238	10,898	Redacted
TX_RET_DSD	Total number of adults and children	5,216	13,290	Redacted



	who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up			
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	120	63	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	151	63	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	45	63	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	75	0	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	120	63	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	20	20	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	16	16	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	4	4	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	20	20	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	20	20	Redacted
LAB_CAP_DSD	By site support type: Direct Service	16	16	Redacted



	Delivery (DSD)			
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	4	4	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	20	20	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	41,000	50,613	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	44,062	51,124	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13101</b>	<b>Mechanism Name: ASSIST (former Health Care Improvement) Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 500,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	500,000

### Sub Partner Name(s)

(No data provided.)



**Cross-Cutting Budget Attribution(s)**

Food and Nutrition: Policy, Tools, and Service Delivery	100,000
Economic Strengthening	100,000
Gender: Gender Equality	50,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Gender: GBV	50,000
Focus Area:	GBV Prevention
Motor Vehicles: Leased	15,000

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13101			
<b>Mechanism Name:</b> ASSIST (former Health Care Improvement) Project			
<b>Prime Partner Name:</b> University Research Corporation, LLC			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	400,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	100,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)



### Implementing Mechanism Details

<b>Mechanism ID: 12638</b>	<b>Mechanism Name: Support for Service Delivery-Excellence</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,250,829</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	4,250,829

### Sub Partner Name(s)

Care International	PLAN International	Save the Children US
--------------------	--------------------	----------------------

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	2,550,497
Food and Nutrition: Policy, Tools, and Service Delivery	100,000
Renovation	30,000

### Key Issues

Malaria (PMI)  
 Child Survival Activities  
 Safe Motherhood  
 TB



Family Planning

**Budget Code Information**

<b>Mechanism ID:</b> 12638			
<b>Mechanism Name:</b> Support for Service Delivery-Excellence			
<b>Prime Partner Name:</b> JHPIEGO			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	339,745	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	218,296	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	22,788	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	600,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,770,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	600,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	24,150	
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	25,968	
PMTCT_ARV_NGI	Life-long ART (including Option B+)	26,414	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	16,905	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	7,245	
PMTCT_ARV_NGI	Sum of Regimen disaggregates	26,414	
PMTCT_ARV_NGI	Sum of New and Current disaggregates	24,150	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	24,150	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	25,968	
PMTCT_ARV_TA	Life-long ART (including Option B+)	26,414	



PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	16,905	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	7,245	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	26,414	
PMTCT_ARV_TA	Sum of New and Current disaggregates	24,150	
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	236,077	
PMTCT_STAT_NGI	Number of new ANC and L&D clients	277,737	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	236,077	
PMTCT_STAT_TA	Number of new ANC and L&D clients	277,737	
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	655,768	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	19,696	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	170,476	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	19,696	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	445,900	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	39,392	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	616,376	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	655,768	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	655,768	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	19,696	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	170,476	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	19,696	



HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	445,900	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	39,392	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	616,376	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	655,768	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	91,702	
C2.1.D_NGI	By Age/Sex: <15 Female	4,570	
C2.1.D_NGI	By Age/Sex: <15 Male	3,656	
C2.1.D_NGI	By Age/Sex: 15+ Female	57,777	
C2.1.D_NGI	By Age/Sex: 15+ Male	25,699	
C2.1.D_NGI	Sum of Age/Sex disaggregates	91,702	
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	91,702	
C2.1.D_TA	By Age/Sex: <15 Female	4,570	
C2.1.D_TA	By Age/Sex: <15 Male	3,656	
C2.1.D_TA	By Age/Sex: 15+ Female	57,777	
C2.1.D_TA	By Age/Sex: 15+ Male	25,699	
C2.1.D_TA	Sum of Age/Sex disaggregates	91,702	
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	34,486	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	34,846	
TX_CURR_TA	Aggregated Age/Sex: <15 Female	34,846	
TX_CURR_TA	Sum of Aggregated Age/Sex <15	34,846	
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	34,846	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,943	12,730
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	12,943	7,295
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	12,943	12,730

## Implementing Mechanism Details

Approved



<b>Mechanism ID: 12131</b>	<b>Mechanism Name: Christian Health Association of Malawi</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Christian Health Association of Malawi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: PR/SR	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,100,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,100,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	500,000
----------------------------	---------

**Key Issues**

- Malaria (PMI)
- Child Survival Activities
- Mobile Population
- Safe Motherhood
- TB
- Workplace Programs
- Family Planning



**Budget Code Information**

<b>Mechanism ID:</b> 12131			
<b>Mechanism Name:</b> Christian Health Association of Malawi			
<b>Prime Partner Name:</b> Christian Health Association of Malawi			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	5,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	5,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	110,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	736,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	114,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	5,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	900,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	125,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	20	18	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	20	18	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	20	18	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	20	18	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	20	18	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	20	18	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	4	5	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	19	19	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,000	2,452	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,000	2,581	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	2,000	2,452	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current	2,000	2,452	Redacted



	pregnancy			
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	2,000	2,452	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	2,000	2,452	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,000	2,150	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,000	2,150	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	2,000	2,150	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	2,000	2,150	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	20	20	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	20	20	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	20	20	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	20	20	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	20	20	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of	0	0	Redacted



	PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)			
PMTCT_SITE	Sum of Denominator Support Type disaggregates	20	20	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18,800	23,229	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	18,800	24,451	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	1,880	13,473	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,880	9,756	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	3,760	23,229	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18,800	19,928	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	18,800	19,928	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	1,880	1,993	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	1,880	1,993	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	3,760	3,986	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	20,000	20,000	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	15,000	15,000	Redacted

PMTCT_STAT_TA	By: Known positives at entry	18,000	18,000	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	2,000	2,000	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	20,000	20,000	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	30	75	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	30	75	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	20	50	Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	10	25	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	36	90	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	30	75	Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	6	15	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male	2,000	5,000	Redacted

	circumcision (VMMC) for HIV prevention program within the reporting period			
VMMC_CIRC_DS D	By Age: <1	0	0	Redacted
VMMC_CIRC_DS D	By Age: 1-9	0	0	Redacted
VMMC_CIRC_DS D	By Age: 10-14	494	1,234	Redacted
VMMC_CIRC_DS D	By Age: 15-19	633	1,583	Redacted
VMMC_CIRC_DS D	By Age: 20-24	333	1,333	Redacted
VMMC_CIRC_DS D	By Age: 25-49	440	600	Redacted
VMMC_CIRC_DS D	By Age: 50+	100	250	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	2,000	5,000	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	200	500	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	1,800	4,500	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	2,000	5,000	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	1,300	3,250	Redacted
VMMC_CIRC_DS	By follow-up status: Number of	700	1,750	Redacted



D	surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery			
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	2,000	5,000	Redacted
VMMC_CIRC_NGI	By Age: <1	100	250	Redacted
VMMC_CIRC_NGI	By Age: 1-9	600	1,500	Redacted
VMMC_CIRC_NGI	By Age: 10-14	260	650	Redacted
VMMC_CIRC_NGI	By Age: 15-19	400	1,000	Redacted
VMMC_CIRC_NGI	By Age: 20-24	300	750	Redacted
VMMC_CIRC_NGI	By Age: 25-49	240	600	Redacted
VMMC_CIRC_NGI	By Age: 50+	100	250	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	2,000	5,000	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	200	500	Redacted
VMMC_CIRC_NGI	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	1,800	4,500	Redacted
VMMC_CIRC_NGI	By circumcision technique: Surgical VMMC	2,000	5,000	Redacted
VMMC_CIRC_NGI	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	1,300	3,250	Redacted
VMMC_CIRC_NGI	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	700	1,750	Redacted



KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	6,667	8,334	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	6,667	6,667	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	31,030	104,477	Redacted
HTC_TST_DSD	By Test Result: Negative	27,927	9,370	Redacted
HTC_TST_DSD	By Test Result: Positive	3,103	10,726	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	31,030	20,096	Redacted
HTC_TST_DSD	Age/sex: <1 Male	745	629	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	1,787	2,517	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	2,681	2,455	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	1,936	2,091	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	2,979	5,742	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	2,234	4,774	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	1,787	13,624	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	745	4,369	Redacted
HTC_TST_DSD	Age/sex: <1 Female	807	611	Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	1,936	2,445	Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	2,904	2,484	Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	2,098	2,156	Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	3,227	11,868	Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	2,420	9,969	Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	1,937	28,792	Redacted



HTC_TST_DSD	Age/sex: 50+ Female	807	9,951	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	31,030	104,477	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,149	7,693	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	7,745	28,508	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,745	7,697	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,391	60,579	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	14,894	15,390	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	16,136	89,087	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	31,030	104,477	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	31,030	33,357	Redacted
HTC_TST_NGI	By Test Result: Negative	27,927	30,021	Redacted
HTC_TST_NGI	By Test Result: Positive	3,103	3,336	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	31,030	33,357	Redacted
HTC_TST_NGI	Age/sex: <1 Male	745	801	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	1,787	1,921	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	2,681	2,882	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	1,936	2,081	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	2,979	3,202	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	2,234	2,402	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	1,787	1,921	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	745	801	Redacted
HTC_TST_NGI	Age/sex: <1 Female	807	867	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	1,936	2,082	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	2,904	3,122	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	2,098	2,255	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	3,227	3,469	Redacted

HTC_TST_NGI	Age/sex: 20-24 Female	2,420	2,602	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	1,937	2,082	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	807	867	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	31,030	33,357	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	931	1,001	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	13,653	14,677	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	2,172	2,335	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	14,274	15,344	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	3,103	3,336	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	27,927	30,021	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	31,030	33,357	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	16,000	45,704	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	3,994	1,969	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	3,686	1,968	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	4,326	27,566	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	3,994	14,201	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	16,000	45,704	Redacted
C2.1.D_DSD	By Age: <15	7,680	3,937	Redacted
C2.1.D_DSD	By Age: 15+	8,320	41,767	Redacted
C2.1.D_DSD	Sum of Age disaggregates	16,000	45,704	Redacted
C2.1.D_DSD	By Sex: Female	8,320	29,535	Redacted
C2.1.D_DSD	By Sex: Male	7,680	16,168	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	16,000	45,703	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	16,000	20,000	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	3,994	4,992	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	3,686	4,608	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	4,326	5,408	Redacted

C2.1.D_NGI	By Age/Sex: 15+ Male	3,994	4,992	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	16,000	20,000	Redacted
C2.1.D_NGI	By Age: <15	7,680	9,600	Redacted
C2.1.D_NGI	By Age: 15+	8,320	10,400	Redacted
C2.1.D_NGI	Sum of Age disaggregates	16,000	20,000	Redacted
C2.1.D_NGI	By Sex: Female	8,320	10,400	Redacted
C2.1.D_NGI	By Sex: Male	7,680	9,600	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	16,000	20,000	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	16,000	43,500	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	16,000	45,704	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	800	100	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	16,000	45,704	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	16,000	45,703	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	384	161	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	922	644	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	1,382	628	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	998	535	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	1,536	2,860	Redacted



CARE_CURR_DS D	Age/sex: 20-24 Male	1,152	2,378	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	922	6,786	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	384	2,176	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	416	156	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	998	626	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	1,498	635	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	1,082	552	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	1,664	5,400	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	1,248	4,536	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	998	13,102	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	416	4,528	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	16,000	45,703	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,686	4,608	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,994	4,992	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,994	4,992	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,326	5,408	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	16,000	20,000	Redacted



CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	16,000	10,190	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	384	54	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	922	216	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	1,382	210	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	998	179	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	1,536	607	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	1,152	505	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	922	1,441	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	384	462	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	416	52	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	998	210	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	1,498	213	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	1,082	185	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	1,664	1,147	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	1,248	963	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	998	2,783	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	416	962	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	16,000	10,189	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	3,686	605	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	3,994	3,994	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	3,994	660	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	4,326	5,855	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	16,000	11,114	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical	20	18	Redacted

	assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole			
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	20	18	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	20	18	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	20	18	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	20	18	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	20	18	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period	20	18	Redacted
TB_ARTSITE	The number of PEPFAR-supported TB basic management units	20	18	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are	20	18	Redacted

	HIV-positive are on ART, during the reporting period			
TB_ARTSITE	Sum of Numerator Site Support Type disaggregates	20	18	Redacted
TB_ARTSITE	By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units	20	18	Redacted
TB_ARTSITE	Sum of Denominator Site Support Type disaggregates	20	18	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,735	2,169	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	3,000	3,330	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,192	1,490	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,192	1,490	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	543	679	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	11,624	45,704	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	279	161	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	670	644	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	1,730	1,163	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	2,902	14,201	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	302	156	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	725	626	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	1,874	1,187	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	3,142	27,566	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	5,580	3,937	Redacted



TX_CURR_DSD	Aggregated Age/Sex: <1 Male	279	307	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	302	332	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,399	12,669	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,902	7,582	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,599	10,859	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,143	10,657	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,998	23,528	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	6,045	18,239	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	11,043	41,767	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	11,624	12,786	Redacted
TX_CURR_NGI	Age/Sex: <1 Male	279	307	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	670	736	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	1,730	1,903	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	2,902	3,191	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	302	332	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	725	798	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	1,874	2,062	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	3,142	3,457	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	11,624	12,786	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	279	307	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	302	332	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	2,399	2,639	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	2,902	3,191	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	2,599	2,859	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	3,143	3,457	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	11,043	12,146	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	4,998	5,498	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	6,045	6,648	Redacted
TX_DIST	Number of Districts with documented	15	15	Redacted



	routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District			
TX_DIST	Total number of PEPFAR supported District Health Offices	15	15	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,540	10,190	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	37	54	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	89	216	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	133	210	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	96	179	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	148	607	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	112	505	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	89	1,441	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	37	462	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	40	52	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	96	210	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	144	213	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	104	185	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	160	1,147	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	120	963	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	96	2,783	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	39	962	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,540	10,189	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	37	54	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	318	659	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	384	3,016	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	40	52	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	344	660	Redacted



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	417	5,855	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,463	10,190	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,752	9,007	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,600	10,190	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	330	360	Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,838	3,093	Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,432	3,741	Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,600	7,194	Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning	2,838	3,093	Redacted



	of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,432	3,741	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	20	18	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	20	18	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	20	18	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	20	18	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	20	18	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	20	18	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such	2	3	Redacted

	accreditation			
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	2	3	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	2	3	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	4	6	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	19	18	Redacted
LAB_CAP_DSD	By clinical laboratories	19	18	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	19	18	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	17	18	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	2	0	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	19	18	Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	19	18	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	19	18	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	66	66	Redacted
HRH_PRE	By Graduates: Nurses	66	66	Redacted
HRH_PRE	By Graduates: Other	57		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	123	66	Redacted



HRH_PRE	By new graduates who are licensed and registered: Nurses	66	66	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	14,800	43,300	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	16,000	45,703	Redacted
TB_SCREEN_DSD	Age: <1	800	1,000	Redacted
TB_SCREEN_DSD	Age: 1-4	1,920	2,400	Redacted
TB_SCREEN_DSD	Age: 5-9	2,880	3,600	Redacted
TB_SCREEN_DSD	Age: 10-14	2,080	2,600	Redacted
TB_SCREEN_DSD	Age: 15-19	3,200	4,000	Redacted
TB_SCREEN_DSD	Age: 20-24	2,400	3,000	Redacted
TB_SCREEN_DSD	Age: 25-49	1,920	2,400	Redacted
TB_SCREEN_DSD	Age: 50+	800	1,000	Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	10,880	13,600	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	7,680	9,600	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	8,320	10,400	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	16,000	20,000	Redacted
TB_SCREEN_DSD	Sex: Male	7,680	9,600	Redacted
TB_SCREEN_DSD	Sex: Female	8,320	10,400	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	16,000	20,000	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12130</b>	<b>Mechanism Name: Baylor College of Medicine</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor College of Medicine Children's Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 5,727,630</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,217,130
GHP-USAID	1,510,500

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	3,436,578
Gender: Gender Equality	319,500
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	12130		
<b>Mechanism Name:</b>	Baylor College of Medicine		
<b>Prime Partner Name:</b>	Baylor College of Medicine Children's Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HBHC	607,630	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	1,435,150	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	400,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	584,850	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	1,900,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2014	2015
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of	2,459	753



	mother-to-child-transmission (MTCT) during pregnancy and delivery		
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,502	849
PMTCT_ARV_DSD	Life-long ART (including Option B+)	2,459	753
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,721	377
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	738	376
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	2,459	753
PMTCT_ARV_DSD	Sum of New and Current disaggregates	2,459	753
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,531	
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,578	
PMTCT_ARV_NGI	Life-long ART (including Option B+)	2,523	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,461	
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,062	
PMTCT_ARV_NGI	Sum of Regimen disaggregates	2,523	



PMTCT_ARV_NGI	Sum of New and Current disaggregates	2,523	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	162	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	173	
PMTCT_ARV_TA	Life-long ART (including Option B+)	162	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	113	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	49	
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	162	
PMTCT_ARV_TA	Sum of New and Current disaggregates	162	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,099	12,429
PMTCT_STAT_DSD	Number of new ANC and L&D clients	31,672	13,468
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	29,975	
PMTCT_STAT_NGI	Number of new ANC and L&D clients	33,872	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,876	



PMTCT_STAT_TA	Number of new ANC and L&D clients	2,200	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	48,215	120,611
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,426	45,035
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,453	10,628
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,343	45,035
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	31,993	19,913
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	7,769	90,070
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	40,446	30,541
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	48,215	120,611
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	50,201	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	2,500	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	8,729	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	5,595	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	33,377	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	8,095	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	42,106	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	50,201	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,986	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	74	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	276	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	252	



HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,384	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	326	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	1,660	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	1,986	
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	12,419	
C2.1.D_DSD	By Age/Sex: <15 Female	2,710	
C2.1.D_DSD	By Age/Sex: <15 Male	2,581	
C2.1.D_DSD	By Age/Sex: 15+ Female	7,128	
C2.1.D_DSD	By Age/Sex: 15+ Male	0	
C2.1.D_DSD	Sum of Age/Sex disaggregates	12,419	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	13,427	
C2.1.D_NGI	By Age/Sex: <15 Female	2,871	
C2.1.D_NGI	By Age/Sex: <15 Male	2,686	
C2.1.D_NGI	By Age/Sex: 15+ Female	7,870	
C2.1.D_NGI	By Age/Sex: 15+ Male	0	
C2.1.D_NGI	Sum of Age/Sex disaggregates	13,427	
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	1,008	
C2.1.D_TA	By Age/Sex: <15 Female	161	
C2.1.D_TA	By Age/Sex: <15 Male	105	
C2.1.D_TA	By Age/Sex: 15+ Female	742	
C2.1.D_TA	By Age/Sex: 15+ Male	0	
C2.1.D_TA	Sum of Age/Sex disaggregates	1,008	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	9,940	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	12,419	
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	51	



C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	12,419	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,489	9,544
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	2,502	19,087
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	9,092	27,101
TX_CURR_DSD	Age/Sex: 15+ Male	0	2,700
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,103	9,693
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	0	2,700
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,113	9,693
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,876	5,015
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,216	19,386
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	4,876	7,715
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	9,092	27,101
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	9,242	
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	2,121	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	0	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	2,133	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	4,988	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	9,242	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	4,254	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	4,988	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	451	
TX_CURR_TA	Aggregated Age/Sex: <15 Male	55	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	0	
TX_CURR_TA	Aggregated Age/Sex: <15 Female	60	



TX_CURR_TA	Aggregated Age/Sex: 15+ Female	336	
TX_CURR_TA	Sum of Aggregated Age/Sex <15	115	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	336	
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	451	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,294	8,013
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	314	2,960
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	0	749
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	320	2,960
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,660	1,344
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,294	8,013
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	9,940	25,426

### Implementing Mechanism Details

<b>Mechanism ID: 12126</b>	<b>Mechanism Name: Feed/OVC/GHAI</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Feed the Children	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 790,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	790,000

### Sub Partner Name(s)

Approved



Total Land Care	World Relief Corporation	
-----------------	--------------------------	--

**Cross-Cutting Budget Attribution(s)**

Food and Nutrition: Policy, Tools, and Service Delivery	316,000
Economic Strengthening	237,000
Education	237,000
Gender: Gender Equality	237,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Water	316,000
Construction	141,966

**Key Issues**

Child Survival Activities

**Budget Code Information**

<b>Mechanism ID:</b>	12126		
<b>Mechanism Name:</b>	Feed/OVC/GHAI		
<b>Prime Partner Name:</b>	Feed the Children		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	790,000	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2014	2015
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	167,745	169,731

### Implementing Mechanism Details

<b>Mechanism ID: 12119</b>	<b>Mechanism Name: Building the Nursing Workforce and Nursing Training Capacity in Malawi</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Global AIDS Interfaith Alliance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 389,982</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	389,982

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	389,982
Motor Vehicles: Leased	19,845

### Key Issues

Child Survival Activities



Safe Motherhood

**Budget Code Information**

<b>Mechanism ID:</b>	12119		
<b>Mechanism Name:</b>	Building the Nursing Workforce and Nursing Training Capacity in		
<b>Prime Partner Name:</b>	Malawi		
	Global AIDS Interfaith Alliance		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	389,982	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2014	2015
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	47	91
HRH_PRE	By Graduates: Nurses	47	91
HRH_PRE	Sum of Graduates disaggreagtes	47	91

**Implementing Mechanism Details**

<b>Mechanism ID: 12118</b>	<b>Mechanism Name: BLM CIRC GHAI</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Banja La Mtsogolo	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Approved



<b>Total All Funding Sources: 1,000,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	707,685
GHP-USAID	292,315

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	31,027
Motor Vehicles: Purchased	28,806
Gender: Gender Equality	109,162
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Condom programming	109,162

### Key Issues

End-of-Program Evaluation  
Family Planning

### Budget Code Information



<b>Mechanism ID:</b> 12118			
<b>Mechanism Name:</b> BLM CIRC GHAI			
<b>Prime Partner Name:</b> Banja La Mtsogolo			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,000,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	175	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	17,400	16,129
VMMC_CIRC_DSD	By Age: 10-14	4,002	4,796
VMMC_CIRC_DSD	By Age: 15-19	6,090	4,491
VMMC_CIRC_DSD	By Age: 20-24	3,480	3,558
VMMC_CIRC_DSD	By Age: 25-49	3,132	2,742
VMMC_CIRC_DSD	By Age: 50+	696	542
VMMC_CIRC_DSD	Sum of age disaggregates	17,400	16,129
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	17,400	
VMMC_CIRC_NGI	By Age: 10-14	4,002	
VMMC_CIRC_NGI	By Age: 15-19	6,090	
VMMC_CIRC_NGI	By Age: 20-24	3,480	
VMMC_CIRC_NGI	By Age: 25-49	3,132	
VMMC_CIRC_NGI	By Age: 50+	696	
VMMC_CIRC_NGI	Sum of Age disaggregates	17,400	



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	16,885	15,322
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,000	4,597
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,885	10,725
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	5,000	4,597
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	11,885	10,725
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	16,885	15,322
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	16,885	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	5,000	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	11,885	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	5,000	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	11,885	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	16,885	

### Implementing Mechanism Details

<b>Mechanism ID: 12116</b>	<b>Mechanism Name: ASGF/State for Ambassadors Small Grant for HIV/AIDS</b>
Funding Agency: State/AF	Procurement Type: Cooperative Agreement
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 75,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>



GHP-State	75,000
-----------	--------

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Economic Strengthening	20,000
------------------------	--------

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 12116			
<b>Mechanism Name:</b> ASGF/State for Ambassadors Small Grant for HIV/AIDS			
<b>Prime Partner Name:</b> U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	45,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	30,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	1	1
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery	4	4



	(DSD)		
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	2	2
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	420	420
PP_PREV_DSD	Total number of people in the target population	420	420
PP_PREV_DSD	Age/sex: 10-14 Male	70	70
PP_PREV_DSD	Age/sex: 15-19 Male	70	70
PP_PREV_DSD	Age/sex: 20-24 Male	70	70
PP_PREV_DSD	Age/sex: 10-14 Female	70	70
PP_PREV_DSD	Age/sex: 15-19 Female	70	70
PP_PREV_DSD	Age/sex: 20-24 Female	70	70
PP_PREV_DSD	Sum of Age/Sex disaggregates	420	420
HTC_TST_NA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,120	2,120
HTC_TST_NA	Aggregated Age/sex: <15 Male	530	530
HTC_TST_NA	Aggregated Age/sex: 15+ Male	530	530
HTC_TST_NA	Aggregated Age/sex: <15 Female	530	530
HTC_TST_NA	Aggregated Age/sex: 15+ Female	530	530
HTC_TST_NA	Sum of Aggregated Age/Sex <15	1,060	1,060
HTC_TST_NA	Sum of Aggregated Age/Sex 15+	1,060	1,060
HTC_TST_NA	Sum of Aggregated Age/Sex disaggregates	2,120	2,120
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,320	2,320
HTC_TST_NGI	Aggregated Age/sex: <15 Male	580	580
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	580	580
HTC_TST_NGI	Aggregated Age/sex: <15 Female	580	580
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	580	580



HTC_TST_NGI	Sum of Aggregated Age/Sex <15	1,160	1,160
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	1,160	1,160
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	2,320	2,320
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	200	200
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	50	50
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	50	50
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	50	50
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	50	50
HTC_TST_TA	Sum of Aggregated Age/Sex <15	100	100
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	100	100
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	200	200
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	700	700

### Implementing Mechanism Details

<b>Mechanism ID: 12111</b>	<b>Mechanism Name: Supporting implementation of National AIDS Framework through improving coverage and quality of HIV and AIDS Services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Malawi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: PR/SR	
G2G: Yes	Managing Agency: HHS/CDC
<b>Total All Funding Sources: 2,704,088</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	



FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	2,704,088

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	500,000
----------------------------	---------

### Key Issues

Malaria (PMI)  
 Child Survival Activities  
 Mobile Population  
 Safe Motherhood  
 TB  
 Family Planning

### Budget Code Information

<b>Mechanism ID:</b>	12111		
<b>Mechanism Name:</b>	Supporting implementation of National AIDS Framework through		
<b>Prime Partner Name:</b>	improving coverage and quality of HIV and AIDS Services		
	Ministry of Health, Malawi		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	28,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	39,068	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	140,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	125,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,956,250	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	115,020	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	671	671	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	671	671	Redacted
SITE_SUPP	By program area/support type: Care	671	671	Redacted



	and Support Technical Assistance-only (TA)			
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	671	671	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12110</b>	<b>Mechanism Name: University of Malawi College of Medicine</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Malawi College of Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: PR/SR	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,000,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,000,000

### Sub Partner Name(s)

Loma Linda University	University of North Carolina	
-----------------------	------------------------------	--

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
Gender: Gender Equality	10,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building



**Key Issues**

- Malaria (PMI)
- Child Survival Activities
- Safe Motherhood
- TB
- Family Planning

**Budget Code Information**

<b>Mechanism ID:</b> 12110			
<b>Mechanism Name:</b> University of Malawi College of Medicine			
<b>Prime Partner Name:</b> University of Malawi College of Medicine			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	350,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2014	2015	Planning Budget
------------------	-------	------	------	-----------------



				Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	18	1	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	18	1	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	5	1	Redacted
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	5		Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	18	1	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	18	1	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	500	435	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	500	492	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	500	435	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	400	217	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	100	218	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	500	435	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	500	435	Redacted



PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	500	500	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	500	500	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	500	500	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	400	400	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	100	100	Redacted
PMTCT_ARV_NGI	Sum of Regimen disaggregates	500	500	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	500	500	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	500	2,007	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	2,000	2,334	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	400	231	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	100	261	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	500	492	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	500	500	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	2,000	2,000	Redacted

PMTCT_STAT_NG I	By: Known positives at entry	100	100	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	400	400	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	500	500	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	36,900	43,400	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	2,214	2,604	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	1,476	1,736	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	19,926	23,436	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	13,284	15,624	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	36,900	43,400	Redacted
C2.1.D_DSD	By Age: <15	3,690	4,340	Redacted
C2.1.D_DSD	By Age: 15+	33,210	39,060	Redacted
C2.1.D_DSD	Sum of Age disaggregates	36,900	43,400	Redacted
C2.1.D_DSD	By Sex: Female	22,140	26,040	Redacted
C2.1.D_DSD	By Sex: Male	14,760	17,360	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	36,900	43,400	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	36,900	36,900	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	2,214	2,214	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	1,476	1,476	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	19,926	19,926	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	13,284	13,284	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	36,900	36,900	Redacted
C2.1.D_NGI	By Age: <15	3,690	3,690	Redacted
C2.1.D_NGI	By Age: 15+	33,210	33,210	Redacted
C2.1.D_NGI	Sum of Age disaggregates	36,900	36,900	Redacted
C2.1.D_NGI	By Sex: Female	22,140	22,140	Redacted
C2.1.D_NGI	By Sex: Male	14,760	14,760	Redacted



C2.1.D_NGI	Sum of Sex disaggregates	36,900	36,900	Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	31,365	36,890	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	36,900	43,400	Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	1,500	1,600	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	36,900	43,400	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	25,000	25,846	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	200		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	200		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	300		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	300		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	2,000		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	3,000		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	3,000		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	1,000		Redacted
CARE_CURR_DS	Age/sex: <1 Female	300		Redacted



D				
CARE_CURR_DS D	Age/sex: 1-4 Female	300		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	450		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	450		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	3,000		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	4,500		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	4,500		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	1,500		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	25,000		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,000	1,292	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,000	8,788	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,500	1,292	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	13,500	14,474	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	25,000	25,846	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,000	19,597	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	16		Redacted



CARE_NEW_DSD	Age/sex: 1-4 Male	16		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	24		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	24		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	160		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	240		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	240		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	80		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	24		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	24		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	36		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	36		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	240		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	360		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	360		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	120		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	2,000		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	80	980	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	720	6,663	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	120	980	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,080	10,974	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	2,000	19,597	Redacted
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	18	18	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	18	18	Redacted
CARE_SITE	By site support type: Direct Service	15	18	Redacted



	Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole			
CARE_SITE	Sum of Numerator Site Support Type disaggregates	15	18	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	18	18	Redacted
CARE_SITE	Sum of Denominator Site Support Type disaggregates	18	18	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,500	1,128	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,500	1,188	Redacted
TB_ART_DSD	Age: 0-4	60	64	Redacted
TB_ART_DSD	Age: 5-14	90	96	Redacted
TB_ART_DSD	Age: 15+	1,350	968	Redacted
TB_ART_DSD	Male	600	452	Redacted
TB_ART_DSD	Female	900	676	Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,500	1,128	Redacted
TB_ART_DSD	Newly tested	1,000	628	Redacted
TB_ART_DSD	Known HIV-positive	500	500	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	1,500	1,128	Redacted



TB_ART_DSD	Aggregated Age: <15	150	160	Redacted
TB_ART_DSD	Aggregated Age: 15+	1,350	968	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,500	1,128	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	10,500	15,624	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	84	49	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	84	441	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	252	489	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	3,780	4,783	Redacted
TX_CURR_DSD	Age/Sex: <1 Female	126	49	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	126	441	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	378	489	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	5,670	8,883	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,050	1,958	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	10	10	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	60	60	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	84	49	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	126	49	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	330	979	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,780	4,783	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	630	979	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,760	8,883	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	960	1,958	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	9,540	13,666	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	10,500	15,624	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	10,500	12,600	Redacted



TX_CURR_NGI	Age/Sex: <1 Male	84	101	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Male	84	101	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Male	252	302	Redacted
TX_CURR_NGI	Age/Sex: 15+ Male	3,780	4,536	Redacted
TX_CURR_NGI	Age/Sex: <1 Female	126	151	Redacted
TX_CURR_NGI	Age/Sex: 1-4 Female	126	151	Redacted
TX_CURR_NGI	Age/Sex: 5-14 Female	378	454	Redacted
TX_CURR_NGI	Age/Sex: 15+ Female	5,670	6,804	Redacted
TX_CURR_NGI	Sum of Age/Sex disaggregates	10,500	12,600	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	84	101	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	126	151	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	420	504	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	3,780	4,536	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	630	756	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	5,670	6,804	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	10,500	12,600	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	1,050	1,260	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	9,450	11,340	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,000	6,978	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	16	53	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	16	316	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	24	105	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	24	53	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	160	518	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	240	518	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	240	936	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	80	148	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	24	53	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	24	316	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	36	105	Redacted

TX_NEW_DSD	By Age/Sex: 10-14 Female	36	53	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	240	962	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	360	962	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	360	1,732	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	120	148	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,000	6,978	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	16	53	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	80	527	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	720	2,120	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	24	53	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	120	527	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,080	3,804	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,000	6,978	Redacted
TX_NEW_DSD	Pregnancy status	500	1,465	Redacted
TX_NEW_DSD	Breastfeeding status	50	419	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,500	5,722	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,000	6,978	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60		Redacted



TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	90		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,350		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	80		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	120		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,800		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	150	200	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12	1,350	1,800	Redacted

	months after initiating ART)			
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	200	250	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,800	2,250	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	1	1	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	1	1	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	1	1	Redacted
TX_SITE	Sum of Numerator Site Support Type disaggregates	1	1	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	1	1	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	1	1	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are	10	8	Redacted



	recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation			
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	10	8	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	10	8	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	27	27	Redacted
LAB_CAP_DSD	By clinical laboratories	18	18	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	9	9	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	27	27	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	27	27	Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	18	18	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	18	18	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	18	18	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	18	18	Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	27	27	Redacted
LAB_PT_DSD	CD4: Number of laboratories that	18	18	Redacted



	participate in this PT program			
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	18	18	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	2	2	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	2	2	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2	2	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	2	2	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	2	2	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2	2	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	18	18	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	18	18	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	18	18	Redacted
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or	54	54	Redacted



	support supply chain, inventory management, supportive supervision or distribution activities			
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	54	54	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to perform inventory management	54	54	Redacted
QI_SITE	Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months	27	27	Redacted
QI_SITE	Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC	27	27	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months	27	27	Redacted
QI_SITE	Sum of Numerator Site Support Type disaggregates	27	27	Redacted
QI_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC	27	27	Redacted



QI_SITE	Sum of Denominator Site Support Type disaggregates	27	27	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	25,000	25,588	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	25,000	25,846	Redacted

**Implementing Mechanism Details**

<b>Mechanism ID: 12109</b>	<b>Mechanism Name: USAID Tuberculosis CARE Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,100,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,094,272
GHP-USAID	5,728

**Sub Partner Name(s)**

Partners in Health	Project HOPE	
--------------------	--------------	--



### Cross-Cutting Budget Attribution(s)

Human Resources for Health	120,000
Renovation	175,000
Motor Vehicles: Leased	10,000
Gender: Gender Equality	80,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Food and Nutrition: Commodities	50,000

### Key Issues

Child Survival Activities

TB

### Budget Code Information

<b>Mechanism ID:</b>	12109		
<b>Mechanism Name:</b>	USAID Tuberculosis CARE Project		
<b>Prime Partner Name:</b>	University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,100,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	93,918	103,309



C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	93,918	103,309
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	93,918	103,309
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	93,918	103,309
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	751	
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	93,918	103,309
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	93,918	103,309

### Implementing Mechanism Details

<b>Mechanism ID: 12107</b>	<b>Mechanism Name: EQUIP</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Partners in Hope	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,989,322</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,861,194
GHP-USAID	2,128,128

### Sub Partner Name(s)

Baylor College of Medicine	Elizabeth Glaser Pediatric AIDS	University of California at Los
----------------------------	---------------------------------	---------------------------------



Children's Foundation	Foundation	Angeles
-----------------------	------------	---------

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	2,993,593
Renovation	420,500
Motor Vehicles: Purchased	40,000
Gender: Gender Equality	50,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

**Key Issues**

- Safe Motherhood
- TB
- Family Planning

**Budget Code Information**

<b>Mechanism ID:</b>	12107		
<b>Mechanism Name:</b>	EQUIP		
<b>Prime Partner Name:</b>	Partners in Hope		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	845,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	402,633	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	300,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,779,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	562,689	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,965	
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including	2,081	



	known HIV-positive at entry)		
PMTCT_ARV_NGI	Life-long ART (including Option B+)	1,965	
PMTCT_ARV_NGI	Sum of Regimen disaggregates	1,965	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,965	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,081	
PMTCT_ARV_TA	Life-long ART (including Option B+)	1,965	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	1,965	
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,965	
PMTCT_STAT_NGI	Number of new ANC and L&D clients	2,061	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	45,194	
PMTCT_STAT_TA	Number of new ANC and L&D clients	53,176	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,320	180,371
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	713	7,750
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,854	57,374
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	713	7,750
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	11,040	107,497
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,426	15,500
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	17,894	164,871
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	19,320	180,371



HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	156,096	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	4,213	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	48,835	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	4,213	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	98,835	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	8,426	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	147,670	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	156,096	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	136,776	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,500	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	41,981	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,500	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	87,795	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	7,000	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	129,776	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	136,776	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	26,662	
C2.1.D_NGI	By Age/Sex: <15 Female	1,077	
C2.1.D_NGI	By Age/Sex: <15 Male	1,077	
C2.1.D_NGI	By Age/Sex: 15+ Female	16,399	
C2.1.D_NGI	By Age/Sex: 15+ Male	8,109	
C2.1.D_NGI	Sum of Age/Sex disaggregates	26,662	
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	26,662	

C2.1.D_TA	By Age/Sex: <15 Female	1,077	
C2.1.D_TA	By Age/Sex: <15 Male	1,077	
C2.1.D_TA	By Age/Sex: 15+ Female	8,109	
C2.1.D_TA	By Age/Sex: 15+ Male	16,399	
C2.1.D_TA	Sum of Age/Sex disaggregates	26,662	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	13,003	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	10,769	26,662
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	492	
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	10,769	26,662
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,975	1,075
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	1,975	1,075
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,054	1,516
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	2,081	3,031
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	9,976	41,311
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	402	1,677
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,023	13,285
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	402	1,677
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	6,149	24,672
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	804	3,354



TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	9,172	37,957
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	9,976	41,311
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	29,853	
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	1,206	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	9,079	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	1,206	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	18,362	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	29,853	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	2,412	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	27,441	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	19,877	
TX_CURR_TA	Aggregated Age/Sex: <15 Male	804	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	6,056	
TX_CURR_TA	Aggregated Age/Sex: <15 Female	804	
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	12,213	
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,608	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	18,269	
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	19,877	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,732	10,710
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	45	339
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	547	3,586
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	45	339
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,095	6,446
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,732	10,710
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,307	8,782
TX_RET_DSD	Total number of adults and children who	1,538	10,710



	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1	6
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	1	6
LAB_ACC_DSD	Sum of Support Type disaggregates	1	6
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	5	45
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	2	45
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	3	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	5	45
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	13,003	38,320

### Implementing Mechanism Details

<b>Mechanism ID: 12105</b>	<b>Mechanism Name: Support for Health Systems Strengthening and HIV/AIDS Service Delivery in Malawi's South-East Zone</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Dignitas International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Approved



<b>Total All Funding Sources: 5,281,612</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,281,612

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	3,168,967
Renovation	46,195

**Key Issues**

- Child Survival Activities
- Safe Motherhood
- TB
- Workplace Programs
- Family Planning

**Budget Code Information**

<b>Mechanism ID:</b>	12105		
<b>Mechanism Name:</b>	Support for Health Systems Strengthening and HIV/AIDS Service Delivery in Malawi's South-East Zone		
<b>Prime Partner Name:</b>	Dignitas International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,433,150	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HVTB	410,219	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	268,789	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	184,604	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	600,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,734,850	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	300,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who	326	15,597



	received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery		
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	378	17,146
PMTCT_ARV_DSD	Life-long ART (including Option B+)	327	15,597
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	185	7,798
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	142	7,799
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	327	15,597
PMTCT_ARV_DSD	Sum of New and Current disaggregates	327	15,597
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	12,166	
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	14,063	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	11,840	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	13,685	



PMTCT_ARV_TA	Life-long ART (including Option B+)	11,840	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	8,020	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,820	
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	11,840	
PMTCT_ARV_TA	Sum of New and Current disaggregates	11,840	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,259	152,092
PMTCT_STAT_DSD	Number of new ANC and L&D clients	2,501	168,138
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	137,574	
PMTCT_STAT_NGI	Number of new ANC and L&D clients	178,351	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	135,315	
PMTCT_STAT_TA	Number of new ANC and L&D clients	175,850	
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	406,859	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	7,181	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	112,623	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	17,224	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	269,831	



HTC_TST_NGI	Sum of Aggregated Age/Sex <15	24,405	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	382,454	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	406,859	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	406,859	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,181	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	112,623	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	17,224	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	269,831	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	24,405	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	382,454	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	406,859	
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	7,032	
C2.1.D_DSD	By Age/Sex: <15 Female	385	
C2.1.D_DSD	By Age/Sex: <15 Male	250	
C2.1.D_DSD	By Age/Sex: 15+ Female	3,900	
C2.1.D_DSD	By Age/Sex: 15+ Male	2,497	
C2.1.D_DSD	Sum of Age/Sex disaggregates	7,032	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	155,000	
C2.1.D_NGI	By Age/Sex: <15 Female	8,931	
C2.1.D_NGI	By Age/Sex: <15 Male	5,908	
C2.1.D_NGI	By Age/Sex: 15+ Female	85,349	
C2.1.D_NGI	By Age/Sex: 15+ Male	54,812	
C2.1.D_NGI	Sum of Age/Sex disaggregates	155,000	
C2.1.D_TA	Number of HIV-positive individuals receiving a minimum of one clinical service	147,968	



C2.1.D_TA	By Age/Sex: <15 Female	8,546	
C2.1.D_TA	By Age/Sex: <15 Male	5,658	
C2.1.D_TA	By Age/Sex: 15+ Female	81,449	
C2.1.D_TA	By Age/Sex: 15+ Male	52,315	
C2.1.D_TA	Sum of Age/Sex disaggregates	147,968	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	5,774	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	7,032	
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	7,032	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	79	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	668	30,671
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	101	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,034	50,517
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,882	81,188
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	279	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	340	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,781	121,880
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	228	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,210	42,658
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	398	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,945	79,222
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	626	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	6,155	121,880
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	6,781	121,880



TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	148,311	
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	6,053	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	48,108	
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	9,641	
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	84,509	
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	148,311	
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	15,694	
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	132,617	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	141,530	0
TX_CURR_TA	Aggregated Age/Sex: <15 Male	5,825	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	45,898	
TX_CURR_TA	Aggregated Age/Sex: <15 Female	9,243	
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	80,564	
TX_CURR_TA	Sum of Aggregated Age/Sex <15	15,068	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	126,462	
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	141,530	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,160	35,084
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	40	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	394	12,543
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	98	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	628	22,541
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,160	35,084
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	194	28,769
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	255	35,084



	those who have died, those who have stopped ART, and those lost to follow-up		
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	81	81
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	5,774	129,374

### Implementing Mechanism Details

<b>Mechanism ID: 11453</b>	<b>Mechanism Name: Peace Corps Volunteers</b>
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 77,145</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 241,724</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	77,145

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Education	50,000
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building



Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 11453			
<b>Mechanism Name:</b> Peace Corps Volunteers			
<b>Prime Partner Name:</b> U.S. Peace Corps			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	25,158	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	13,677	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	21,549	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	6,761	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	10,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 10427</b>	<b>Mechanism Name: Malawi Blood Transfusion Service</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Malawi Blood Transfusion Service	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: PR/SR	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 1,760,868</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
Funding Source	Funding Amount
GHP-State	1,760,868

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
Motor Vehicles: Purchased	205,000



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b>	10427		
<b>Mechanism Name:</b>	Malawi Blood Transfusion Service		
<b>Prime Partner Name:</b>	Malawi Blood Transfusion Service		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	1,760,868	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	35	35	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	35	35	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	35	35	Redacted
BS_COLL	Number of whole blood collections each year by the NBTS network	70,000	70,000	Redacted
BS_COLL	By: Number of whole blood donations screened for HIV in an NBTS network laboratory	70,000	70,000	Redacted
BS_COLL	By: Number of whole blood donations	3,500	3,500	Redacted



	screened for HIV in an NBTS network laboratory that are identified as reactive for HIV			
--	--	--	--	--

**Implementing Mechanism Details**

<b>Mechanism ID: 9883</b>	<b>Mechanism Name: Prevention for Populations and Settings with High Risk Behaviors</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,200,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,200,000

**Sub Partner Name(s)**

Pact Malawi		
-------------	--	--

**Cross-Cutting Budget Attribution(s)**

Gender: Gender Equality	248,983
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation

**Key Issues**



End-of-Program Evaluation  
Family Planning

### Budget Code Information

<b>Mechanism ID:</b> 9883			
<b>Mechanism Name:</b> Prevention for Populations and Settings with High Risk Behaviors			
<b>Prime Partner Name:</b> Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,200,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	353	100
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	17,658	5,000
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	17,658	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	99,100	



KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	9,100	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	42,215	24,890
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,201	7,467
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	27,071	17,423
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	700	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	9,143	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	5,901	7,467
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	36,214	17,423
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	42,115	24,890
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	42,215	
HTC_TST_NGI	Aggregated Age/sex: <15 Male	5,201	
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	27,071	
HTC_TST_NGI	Aggregated Age/sex: <15 Female	700	
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	9,143	
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	5,901	
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	36,214	
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	42,115	

### Implementing Mechanism Details

<b>Mechanism ID: 9882</b>	<b>Mechanism Name: JHCOM GHAI - 12159</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

Corporate Graphics	Galaxy Media	National Association of People Living with AIDS in Malawi
Pact Malawi	Save the Children in Malawi	Story Workshop
The International HIV/AIDS Alliance	YONECO	

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

Safe Motherhood  
Workplace Programs  
End-of-Program Evaluation  
Family Planning

### Budget Code Information

<b>Mechanism ID: 9882</b>
---------------------------



<b>Mechanism Name:</b> JHCOM GHAI - 12159			
<b>Prime Partner Name:</b> Johns Hopkins University Bloomberg School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	131,430	
PP_PREV_DSD	Age/sex: 15-19 Male	8,214	
PP_PREV_DSD	Age/sex: 20-24 Male	16,429	
PP_PREV_DSD	Age/sex: 25-49 Male	32,857	
PP_PREV_DSD	Age/sex: 50+ Male	8,214	
PP_PREV_DSD	Age/sex: 15-19 Female	8,214	
PP_PREV_DSD	Age/sex: 20-24 Female	16,429	
PP_PREV_DSD	Age/sex: 25-49 Female	32,857	
PP_PREV_DSD	Age/sex: 50+ Female	8,216	
PP_PREV_DSD	Sum of Age/Sex disaggregates	131,430	
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	49,250	



PP_PREV_TA	Age/sex: 15-19 Male	3,044	
PP_PREV_TA	Age/sex: 20-24 Male	6,088	
PP_PREV_TA	Age/sex: 25-49 Male	12,561	
PP_PREV_TA	Age/sex: 50+ Male	3,044	
PP_PREV_TA	Age/sex: 15-19 Female	3,044	
PP_PREV_TA	Age/sex: 20-24 Female	6,088	
PP_PREV_TA	Age/sex: 25-49 Female	12,337	
PP_PREV_TA	Age/sex: 50+ Female	3,044	
PP_PREV_TA	Sum of Age/Sex disaggregates	49,250	

**Implementing Mechanism Details**

<b>Mechanism ID: 9281</b>	<b>Mechanism Name: I-TECH</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: TA	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 5,198,799</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,198,799

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1,500,000
Motor Vehicles: Purchased	165,000
Gender: Gender Equality	20,000



Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information

**Key Issues**

TB

**Budget Code Information**

<b>Mechanism ID:</b> 9281			
<b>Mechanism Name:</b> I-TECH			
<b>Prime Partner Name:</b> University of Washington			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	140,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	503,458	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	700,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	1,500,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	250,341	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXS	2,055,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	50,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	1	3	Redacted
SITE_SUPP	By program area/support type: VMMC Direct Service Delivery (DSD)	1	3	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	5	270	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	5		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	3		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	2		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	378		Redacted

VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	285		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	90		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	6		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	5		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	1		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	13,500	13,500	Redacted
VMMC_CIRC_DS D	By Age: <1	0	0	Redacted
VMMC_CIRC_DS D	By Age: 1-9	0	0	Redacted
VMMC_CIRC_DS D	By Age: 10-14	405	4,014	Redacted
VMMC_CIRC_DS	By Age: 15-19	2,700	3,759	Redacted

D				
VMMC_CIRC_DS D	By Age: 20-24	6,075	2,978	Redacted
VMMC_CIRC_DS D	By Age: 25-49	4,050	2,295	Redacted
VMMC_CIRC_DS D	By Age: 50+	270	454	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	13,500	13,500	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	260	280	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	13,225	14,400	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	15	20	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	13,200	14,700	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	300	0	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	11,960	13,010	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	1,540	1,690	Redacted
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,700	0	Redacted



VMMC_CIRC_TA	By Age: <1	0	0	Redacted
VMMC_CIRC_TA	By Age: 1-9	0	0	Redacted
VMMC_CIRC_TA	By Age: 10-14	180	0	Redacted
VMMC_CIRC_TA	By Age: 15-19	1,140	0	Redacted
VMMC_CIRC_TA	By Age: 20-24	2,560	0	Redacted
VMMC_CIRC_TA	By Age: 25-49	1,710	0	Redacted
VMMC_CIRC_TA	By Age: 50+	110	0	Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	5,700	0	Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	110	0	Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	5,585	0	Redacted
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	5	0	Redacted
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	5,700	0	Redacted
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0	0	Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	5,050	0	Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	650	0	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	13,780	27,075	Redacted
HTC_TST_DSD	By Test Result: Negative	13,570	24,367	Redacted
HTC_TST_DSD	By Test Result: Positive	210	2,708	Redacted



HTC_TST_DSD	Sum of Test Result disaggregates	13,780	27,075	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	410	8,123	Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	2,750	7,581	Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	6,200	5,957	Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	4,130	4,603	Redacted
HTC_TST_DSD	Age/sex: 50+ Male	290	811	Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	13,780	27,075	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	690	8,123	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	13,090	18,952	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	690	8,123	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	13,090	18,952	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	13,780	27,075	Redacted
HTC_TST_TA	By Test Result: Negative	5,730	6,450	Redacted
HTC_TST_TA	By Test Result: Positive	90	100	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	5,820	6,550	Redacted
HTC_TST_TA	Age/sex: <1 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 5-9 Male	0	0	Redacted
HTC_TST_TA	Age/sex: 10-14 Male	90	100	Redacted
HTC_TST_TA	Age/sex: 15-19 Male	1,165	1,310	Redacted
HTC_TST_TA	Age/sex: 20-24 Male	2,735	3,080	Redacted
HTC_TST_TA	Age/sex: 25-49 Male	1,745	1,965	Redacted
HTC_TST_TA	Age/sex: 50+ Male	85	95	Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	5,820	6,550	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	290	330	Redacted



HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,530	6,220	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	290	330	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	5,530	6,220	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	5,820	6,550	Redacted
SC_TRAIN	Number of individuals who received competency-based, certificate or higher-level training to conduct or support supply chain, inventory management, supportive supervision or distribution activities	4	4	Redacted
SC_TRAIN	Number of individuals who conduct or support supply chain, inventory management, supportive supervision or distribution activities	4	4	Redacted
SC_TRAIN	By: Individuals trained in a nationally- or internationally-recognized pre-service training program	4	4	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to conduct supply chain activities	4	4	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to perform inventory management	4	4	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to develop distribution plans	4	4	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to perform supportive supervision	4	4	Redacted
SC_TRAIN	By: Individuals who passed a competency-based training to perform quantification	4	4	Redacted



**Implementing Mechanism Details**

<b>Mechanism ID: 9276</b>	<b>Mechanism Name: National AIDS Commission, Malawi</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National AIDS Commission, Malawi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: PR/SR	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 507,892</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	507,892

**Sub Partner Name(s)**

Malawi AIDS Counseling Resource Organization		
--	--	--

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	50,000
----------------------------	--------

**Key Issues**

- Safe Motherhood
- Workplace Programs
- Family Planning



### Budget Code Information

<b>Mechanism ID:</b>	9276		
<b>Mechanism Name:</b>	National AIDS Commission, Malawi		
<b>Prime Partner Name:</b>	National AIDS Commission, Malawi		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	507,892	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	3	2	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	3	2	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	3	2	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	3	2	Redacted
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	1	2	Redacted
SITE_SUPP	By program area/support type: General Population Prevention Direct Service Delivery (DSD)	3	2	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	3	2	Redacted
SITE_SUPP	By program area/support type: PHDP/Family Planning & Integration	3	2	Redacted

	Direct Service Delivery (DSD)			
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0	0	Redacted
VMMC_CIRC_NGI	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	180	0	Redacted
VMMC_CIRC_NGI	By Age: 15-19	60	0	Redacted
VMMC_CIRC_NGI	By Age: 20-24	60	0	Redacted
VMMC_CIRC_NGI	By Age: 25-49	60	0	Redacted
VMMC_CIRC_NGI	Sum of Age disaggregates	180	0	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	13		Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	13		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	65,000	32,690	Redacted
HTC_TST_DSD	By Test Result: Negative	5,929	29,421	Redacted
HTC_TST_DSD	By Test Result: Positive	59,071	3,269	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	65,000	32,690	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	650	603	Redacted



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	39,000	10,956	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,300	603	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	24,050	20,528	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,950	1,206	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	63,050	31,484	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	65,000	32,690	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	65,000	65,000	Redacted
HTC_TST_NGI	By Test Result: Negative	5,929	5,929	Redacted
HTC_TST_NGI	By Test Result: Positive	59,071	59,071	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	65,000	65,000	Redacted
HTC_TST_NGI	Age/sex: <1 Male	50	50	Redacted
HTC_TST_NGI	Age/sex: 1-4 Male	1,150	1,150	Redacted
HTC_TST_NGI	Age/sex: 5-9 Male	3,800	3,800	Redacted
HTC_TST_NGI	Age/sex: 10-14 Male	4,000	4,000	Redacted
HTC_TST_NGI	Age/sex: 15-19 Male	8,000	8,000	Redacted
HTC_TST_NGI	Age/sex: 20-24 Male	7,000	7,000	Redacted
HTC_TST_NGI	Age/sex: 25-49 Male	4,000	4,000	Redacted
HTC_TST_NGI	Age/sex: 50+ Male	900	900	Redacted
HTC_TST_NGI	Age/sex: <1 Female	55	55	Redacted
HTC_TST_NGI	Age/sex: 1-4 Female	2,500	2,500	Redacted
HTC_TST_NGI	Age/sex: 5-9 Female	2,800	2,800	Redacted
HTC_TST_NGI	Age/sex: 10-14 Female	6,500	6,500	Redacted
HTC_TST_NGI	Age/sex: 15-19 Female	7,000	7,000	Redacted
HTC_TST_NGI	Age/sex: 20-24 Female	6,800	6,800	Redacted
HTC_TST_NGI	Age/sex: 25-49 Female	5,000	5,000	Redacted
HTC_TST_NGI	Age/sex: 50+ Female	5,445	5,445	Redacted
HTC_TST_NGI	Sum of Age/Sex disaggregates	65,000	65,000	Redacted

HTC_TST_NGI	Aggregated Age/sex: <15 Male	650	650	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	39,000	39,000	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	1,300	1,300	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	24,050	24,050	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	1,950	1,950	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	63,050	63,050	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	65,000	65,000	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	65,000	0	Redacted
HTC_TST_TA	By Test Result: Negative	5,929		Redacted
HTC_TST_TA	By Test Result: Positive	59,071		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	65,000		Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	22,425	4,475	Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	150	60	Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	150	59	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	19,125	2,256	Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	3,000	2,100	Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	22,425	4,475	Redacted
C2.1.D_DSD	By Age: <15	300	119	Redacted
C2.1.D_DSD	By Age: 15+	22,125	4,356	Redacted
C2.1.D_DSD	Sum of Age disaggregates	22,425	4,475	Redacted
C2.1.D_DSD	By Sex: Female	19,275	2,316	Redacted
C2.1.D_DSD	By Sex: Male	3,150	2,159	Redacted
C2.1.D_DSD	Sum of Sex disaggregates	22,425	4,475	Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	22,425	24,667	Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	150	165	Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	150	165	Redacted



C2.1.D_NGI	By Age/Sex: 15+ Female	19,125	21,037	Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	3,000	3,300	Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	22,425	24,667	Redacted
C2.1.D_NGI	By Age: <15	300	330	Redacted
C2.1.D_NGI	By Age: 15+	22,125	24,337	Redacted
C2.1.D_NGI	Sum of Age disaggregates	22,425	24,667	Redacted
C2.1.D_NGI	By Sex: Female	19,275	21,202	Redacted
C2.1.D_NGI	By Sex: Male	3,150	3,465	Redacted
C2.1.D_NGI	Sum of Sex disaggregates	22,425	24,667	Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	22,425	4,475	Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	22,425	4,475	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,748	6,059	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	2	0	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	5		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	3		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	10		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	100		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	250		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	300		Redacted



CARE_CURR_DS D	Age/sex: 50+ Male	88		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	3	0	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	4		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	7		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	10		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	150		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	200		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	600		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	16		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	1,748	0	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8	303	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	828	2,060	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	35	303	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	877	3,393	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	1,748	6,059	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO	7,463		Redacted



	staging) OR CD4 count OR viral load			
CARE_SITE	Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	3	2	Redacted
CARE_SITE	Total number of PEPFAR supported sites providing clinical care services	3	2	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	3	2	Redacted
CARE_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole	3	0	Redacted
CARE_SITE	Sum of Numerator Site Support Type disaggregates	6	2	Redacted
CARE_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services	3	2	Redacted
CARE_SITE	By site support type: Technical	3	0	Redacted



	Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services			
CARE_SITE	Sum of Denominator Site Support Type disaggregates	6	2	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	5,962	4,356	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	99	30	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	2,234	1,483	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	116	30	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	3,513	2,754	Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	215	120	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	4		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	61		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1	60	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	37	1,483	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2	60	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	60	2,754	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3	120	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	97	4,237	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	100	4,357	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,500	566	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	150	7	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	125	3	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	150	44	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	145	44	Redacted



TX_NEW_DSD	By Age/Sex: 25-49 Male	200	80	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	5	12	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	150	3	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	175	81	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	200	81	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	198	146	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	2	12	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,500	566	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	275	33	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	500	180	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	275	33	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	400	320	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,450	566	Redacted
TX_SITE	Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	3	2	Redacted
TX_SITE	Total number of PEPFAR-supported ART sites	5	2	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	5	2	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation	5	5	Redacted



TX_SITE	Sum of Numerator Site Support Type disaggregates	10	7	Redacted
TX_SITE	By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites	5	2	Redacted
TX_SITE	By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites	5	5	Redacted
TX_SITE	Sum of Denominator Site Support Type disaggregates	10	7	Redacted
SI_ME	Existence of a national HIV/AIDS M&E system based on the UNAIDS 12 components model	1	1	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	1,748	5,998	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,748	6,059	Redacted

**Implementing Mechanism Details**

<b>Mechanism ID: 9266</b>	<b>Mechanism Name: DELIVER</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: TA	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 2,330,895</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	

Approved



Funding Source	Funding Amount
GHP-State	2,330,895

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	330,000
Condom procurement	775,816

### Key Issues

Malaria (PMI)  
Child Survival Activities  
Safe Motherhood  
TB  
Family Planning

### Budget Code Information

<b>Mechanism ID:</b> 9266			
<b>Mechanism Name:</b> DELIVER			
<b>Prime Partner Name:</b> John Snow, Inc.			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	2,330,895	0

### Implementing Mechanism Indicator Information

(No data provided.)



### Implementing Mechanism Details

<b>Mechanism ID: 7166</b>	<b>Mechanism Name: Howard University</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Howard University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,000,000</b>	<b>Total Mechanism Pipeline: Redacted</b>
<b>Applied Pipeline Amount: 0</b>	
<b>FY 2013 Burn Rate: Redacted</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,000,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	75,000
Gender: Gender Equality	10,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building

### Key Issues

Malaria (PMI)

Child Survival Activities

TB

Custom



### Budget Code Information

<b>Mechanism ID:</b>	7166		
<b>Mechanism Name:</b>	Howard University		
<b>Prime Partner Name:</b>	Howard University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	400,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	400,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	100,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	25		Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	25		Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	5		Redacted
C2.1.D_DSD	Number of HIV-positive individuals	36,486		Redacted



	receiving a minimum of one clinical service			
C2.1.D_DSD	By Age/Sex: <15 Female	1,989		Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	2,497		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	13,895		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	18,105		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	36,486		Redacted
C2.1.D_DSD	By Age: <15	4,486		Redacted
C2.1.D_DSD	By Age: 15+	32,000		Redacted
C2.1.D_DSD	Sum of Age disaggregates	36,486		Redacted
C2.1.D_DSD	By Sex: Female	15,884		Redacted
C2.1.D_DSD	By Sex: Male	20,602		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	36,486		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	2,000		Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	36,486		Redacted
C2.5.D_DSD	Number of HIV-positive patients in HIV care who started TB treatment	1,000		Redacted
C2.5.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	36,486		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	11,055		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	5,528		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	5,527		Redacted
PMTCT_EID_DSD	By infants who received their first	5,528	0	Redacted

	virologic HIV test between 2 and 12 months of age			
PMTCT_EID_DSD	Sum of Infant Age disaggregates	11,055	0	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	442		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	3		Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	3		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	3		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	25		Redacted
LAB_CAP_DSD	By clinical laboratories	13		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	13		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	26		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	6		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	32		Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	25		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	25		Redacted



LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	25		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	25		Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	25		Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	25		Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	20		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	4		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	4		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	4		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	4		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	12		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of	12		Redacted



	laboratories that participate in this PT program			
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	9		Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	57		Redacted
HRH_PRE	By Graduates: Laboratory professionals	57		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	57		Redacted
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	57		Redacted



**Agency Information - Costs of Doing Business  
U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
USG Staff Salaries and Benefits		157,500	2,342,500	Redacted	2,500,000	1,500,000
<b>Total</b>	<b>0</b>	<b>157,500</b>	<b>2,342,500</b>	<b>0</b>	<b>2,500,000</b>	<b>1,500,000</b>

**U.S. Agency for International Development Other Costs Details**

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		5,000		Redacted	5,000	0
ICASS		30,000		Redacted	30,000	0
Management Meetings/Professional Development		5,000		Redacted	5,000	0
Non-ICASS Administrative Costs		10,000		Redacted	10,000	0
Staff Program Travel		20,000		Redacted	20,000	0



USG Staff Salaries and Benefits		50,000		Redacted	50,000	0
<b>Total</b>	<b>0</b>	<b>120,000</b>	<b>0</b>	<b>0</b>	<b>120,000</b>	<b>0</b>

**U.S. Department of Defense Other Costs Details**

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Computers/IT Services		GHP-State		Redacted	5,000	0
ICASS		GHP-State		Redacted	30,000	0
Management Meetings/Professional Development		GHP-State		Redacted	5,000	0
Non-ICASS Administrative Costs		GHP-State		Redacted	10,000	0

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing	200,000			Redacted	200,000	0
Computers/IT Services	30,000			Redacted	30,000	0
ICASS	777,800	237,700		Redacted	1,015,500	0
Management Meetings/Profes		237,300		Redacted	237,300	0



sional Development						
Non-ICASS Administrative Costs	387,100	155,741		Redacted	542,841	0
Staff Program Travel	0	195,100		Redacted	195,100	0
USG Staff Salaries and Benefits	117,600	2,911,659		Redacted	3,029,259	0
<b>Total</b>	<b>1,512,500</b>	<b>3,737,500</b>	<b>0</b>	<b>0</b>	<b>5,250,000</b>	<b>0</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention Other Costs Details**

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Capital Security Cost Sharing		GAP		Redacted	200,000	0
Computers/IT Services		GAP		Redacted	30,000	0
ICASS		GAP		Redacted	777,800	0
ICASS		GAP		Redacted	777,800	0
ICASS		GHP-State		Redacted	237,700	0
ICASS		GHP-State		Redacted	237,700	0
Management Meetings/Prof essional Development		GHP-State		Redacted	237,300	0
Non-ICASS Administrative Costs		GAP		Redacted	387,100	0
Non-ICASS Administrative		GAP		Redacted	387,100	0



Costs						
Non-ICASS Administrative Costs		GHP-State		Redacted	155,741	0
Non-ICASS Administrative Costs		GHP-State		Redacted	155,741	0

**U.S. Department of State**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		5,970		Redacted	5,970	0
ICASS		25,402		Redacted	25,402	112,782
Management Meetings/Professional Development		15,000		Redacted	15,000	40,521
Non-ICASS Administrative Costs		1,000		Redacted	1,000	36,216
Staff Program Travel		3,000		Redacted	3,000	15,000
USG Staff Salaries and Benefits		144,150		Redacted	144,150	166,909
<b>Total</b>	<b>0</b>	<b>194,522</b>	<b>0</b>	<b>0</b>	<b>194,522</b>	<b>371,428</b>

**U.S. Department of State Other Costs Details**

Category	Item	Funding Source	Description	Planned Amount As	Amount	Applied Pipeline
----------	------	----------------	-------------	-------------------	--------	------------------



				Of Last Q1		
Computers/IT Services		GHP-State		Redacted	5,970	0
ICASS		GHP-State		Redacted	25,402	112,782
Management Meetings/Professional Development		GHP-State		Redacted	15,000	40,521
Non-ICASS Administrative Costs		GHP-State		Redacted	1,000	36,216

**U.S. Peace Corps**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		13,948		Redacted	13,948	0
Management Meetings/Professional Development		15,000		Redacted	15,000	0
Non-ICASS Administrative Costs		247,474		Redacted	247,474	76,731
Peace Corps Volunteer Costs		788,102		Redacted	788,102	291,798
Staff Program Travel		41,728		Redacted	41,728	47,060
USG Staff Salaries and Benefits		110,167		Redacted	110,167	42,687

Approved



<b>Total</b>	<b>0</b>	<b>1,216,419</b>	<b>0</b>	<b>0</b>	<b>1,216,419</b>	<b>458,276</b>
--------------	----------	------------------	----------	----------	------------------	----------------

**U.S. Peace Corps Other Costs Details**

Category	Item	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Computers/IT Services		GHP-State		Redacted	13,948	0
Management Meetings/Professional Development		GHP-State		Redacted	15,000	0
Non-ICASS Administrative Costs		GHP-State		Redacted	247,474	76,731